

522 Rec'd PCT/PTO 22 FEB 2000

Atty. Docket #: PH-98/080

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INTERNATIONAL APPL. NO.: PCT/FR99/03179 :

INTERNATIONAL FILING DATE: -12/17/99- :

APPLICANT: RICHARD DeROSE ET AL :

SERIAL NO: : ART UNIT:

FILED: : EXAMINER:

FOR: "METHOD FOR INCREASING THE CONTENT :
 OF SULPHUR COMPOUNDS AND IN PARTICULAR :
 OF CYSTEINE, METHIONINE AND GLUTATHIONE :
 IN PLANTS AND PLANTS OBTAINED"

Assistant Commissioner for Patents
 Box PCT
 Washington, D.C. 20231

"Express Mail" No.: EK219465165

Date: -FEBRUARY 22, 2000-

I hereby certify that this paper, along with any other paper or fee referred to in this paper as being transmitted herewith, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, postage prepaid, on the date indicated above, addressed to the Asst. Comm. for Patents, Washington, D.C. 20231

- Jean Marshall -
 (Typed or printed name of mailing paper or fee)

Jean M. Marshall
 (Signature of person mailing paper)

**TRANSMITTAL OF APPLICATION PAPERS
 TO U.S. DESIGNATED/ELECTED OFFICE (DO/EO/US)
 CONCERNING A FILING UNDER 35 U.S.C. §371
 (37 CFR 1.494 OR 1.495)**

This Transmittal Letter is based upon PTO Form 1390 (as revised in May, 1993).

The above-identified applicant(s) (jointly with their assignee) have filed an International Application under the P.C.T. and hereby submit(s) to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

511 Rec'd PCT/PTO 22 FEB 2000

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay.
4. ☐ A proper Demand for International Preliminary Examination (IPE) was made to the appropriate Authority (IPEA) within the time period required.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)[2]) --
 - a. ☒ is transmitted herewith (required when not transmitted by International Bureau).
 - b. ☐ has been transmitted by the International Bureau. See WIPO Publication WO
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A (verified) translation of the International Application into the English language is enclosed -with- **Twelve (12) sheets of Drawings**.
7. ☐ Amendments to the (specification and) claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)[3])
 - a. ☐ are transmitted herewith (required if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
 - d. ☐ have not been made and will not be made.
 - e. ☐ will be submitted with the appropriate surcharge.
8. ☐ A translation of the amendments to the claims (and/or the specification) under PCT Article 19 (35 U.S.C. §371(c)[3]) is enclosed or will be submitted with the appropriate surcharge.

9. ☒ An oath or declaration/power of attorney of the inventor(s) (35 U.S.C. §371(c)[4]) will follow.
[] and is attached to the translation of (or a copy of) the International Application.
[] and is attached to the substitute specification.

10. [] A translation of at least the Annexes to the IPE Report under PCT Article 36 (35 U.S.C. §371(c)[5]) is enclosed.

Items 11. to 16. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98 is enclosed.
12. ☒ An Assignment for recording and a separate cover sheet in compliance with 37 CFR 3.28 and 3.31 will follow.
13. ☒ A FIRST preliminary amendment is enclosed.
A SECOND or SUBSEQUENT preliminary amendment is enclosed.
14. [] A substitute specification (including claims, abstract, drawing) is enclosed.
15. [] A change of power of attorney and/or address letter is enclosed.
16. ☒ Other items of information:

- ☒ This application is being filed pursuant to 37 CFR 1.494(c) or 1.495(c), and any missing parts will be filed before expiration of--

[] 22 months from the priority date under 37 CFR 1.494(c), or

☒ 32 months from the priority date under 37 CFR 1.495(c).

- ☒ The undersigned attorney is authorized by the International applicant and by the inventors to enter the National Phase pursuant to 37 CFR 1.494(c) or 1.495(c).

The following additional information relates to the International Application:

International Application No. PCT/FR99/03179

February 22, 2000

- ☒ Receiving Office: France
☒ IPEA (if filing under 37 CFR 1.495): _____
☒ Priority Claim(s) (35 USC §§ 119, 365):
French Appln. FR 98/16163 filed on 12/17/98.
☒ A copy of the International Search Report is
☐ enclosed.
☒ attached to the copy of the International
Application.
☒ A copy of the Receiving Office Request Form is enclosed.

The fee calculation is set forth on the next page of this Transmittal Letter.

International Application No. PCT/FR99/03179

February 22, 2000

FEE CALCULATION SHEET

☒ A check in payment of the filing fee, calculated as follows, is attached (37 CFR 1.492).

Basic Fee..... \$ 840.00

Total Number of claims in
excess of (20) times \$18...X.39...=..... 702.00

Number of independent claims
in excess of (3) times \$78..... -0-

Fee for multiple dependent
claims \$260..... -0-

TOTAL FILING FEE... \$1,542.00

Kindly send us the official filing receipt.

The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Deposit Account No. 03-2775. This is a "general authorization" under 37 CFR 1.25(b), except that no automatic debit of the issue upon allowance is authorized. An additional copy of this page is attached.

Respectfully submitted,

By 

Robert G. McMorrow, Jr.
Reg. No. 30,962
CONNOLLY BOVE LODGE & HUTZ LLP
1220 Market Street
P.O. Box 2207
Wilmington, Delaware 19899
Tel. (302) 658-9141

RGM/ jm
Enclosures (5500*42)
F:\docs\fori\40975 = F:\docs\patn\56657.doc

.....

.....

Claim 12, lines 1 and 2, change "one of claims 1 to 5" to read -- claim 1 -- ;

Please amend claim 24 as follows:

-- **Claim 24.** (amended) Method according to claim 13, characterized in that the SAT is a cytoplasmic SAT of plant origin or an SAT of bacterial origin, and that the SAT is a plant SAT or a native SAT of bacterial origin [as defined in one of claims 3 to 5 or 9 to 11]. --

Claim 25, lines 1 and 2, change "either of claims 23 and 24" to read -- claim 23 -- ;

Claim 27, lines 1 and 2, change "either of claims 25 and 26" to read -- claim 25 -- ;

Claim 29, lines 1 and 2, change "either of claims 27 and 28" to read -- claim 27 -- ;

Please amend claim 32 as follows:

-- **Claim 32.** (amended) Fusion protein according to claim 31, characterized in that the SAT is a cytoplasmic SAT of plant origin or an SAT of bacterial origin, and that the SAT is a plant SAT or a native SAT of bacterial origin [as defined in claims 24 to 30]. --

Claim 33, lines 2 and 3, change "either of claims 31 and 32" to read -- claim 31 -- ;

Please amend claim 40 as follows:

-- **Claim 40.** (amended) Chimeric gene according to [one of claims 34 to 39] claim 34, characterized in that the nucleic acid sequence which encodes an SAT encodes an SAT in that the SAT which is overexpressed in plant cells is a cysteine-sensitive SAT [as defined in claims 2 to 30]. --

Please amend claim 41 as follows:

-- **Claim 41.** (amended) Chimeric gene according to [one of claims 34 to 39] claim 34, characterized in that the nucleic acid sequence which encodes an SAT is the nucleic acid sequence encoding a transit peptide/SAT fusion protein and that the SAT is heterologous with the transit peptide [according to claim 33]. --

Claim 42, line 4, change "one of claims 34 to 41" to read -- claim 34 -- ;

Please amend claim 43 as follows:

-- **Claim 43.** (amended) Method of transforming host organisms, characterized in that at least one nucleic acid sequence according to claim 33, or a chimeric gene comprising a coding sequence as well as heterologous 5' and 3' regulatory sequences, which are able to function in a host organism, and that the coding sequence comprises at least one nucleic acid sequence which encodes an SAT [according to one of claims 34 to 41], is integrated into the genome of the said host organism. --

Please amend claim 44 as follows:

-- **Claim 44.** (amended) Method according to claim 43, by means of the vector [according to claim 42] for transforming a host organism, characterized in that it contains at least one chimeric gene comprising a coding sequence as well as heterologous 5' and 3' regulatory sequences, which are able to function in a host organism, and that the coding sequence comprises at least one nucleic acid sequence which encodes an SAT [according to claim 42]. --

Claim 45, lines 1 and 2, change "either of claims 43 and 44" to read -- claim 43 -- ;

Please amend claim 49 as follows:

-- **Claim 49.** (amended) Transformed host organism, characterized in that it comprises at least one nucleic acid sequence according to claim 33, or a chimeric gene comprising a coding sequence as well as heterologous 5' and 3' regulatory sequences, which are able to function in a host organism, and that the coding sequence comprises at least one nucleic acid sequence which encodes an SAT [according to one of claims 34 to 41]. --

Please amend claim 50 as follows:

-- **Claim 50.** (amended) Host organism according to claim 49, characterized in that it is obtained by the method of transforming host organisms, characterized in that at least one

nucleic acid sequence encoding a transit peptide/SAT fusion protein, characterized in that the SAT is heterologous with the transit peptide, or a chimeric gene comprising a coding sequence as well as heterologous 5' and 3' regulatory sequences, which are able to function in a host organism, and that the coding sequence comprises at least one nucleic acid sequence which encodes an SAT, is integrated into the genome of the said host organism [according to one of claims 43 to 48]. --

Please amend claim 51 as follows:

-- **Claim 51.** (amended) Plant cell, characterized in that it comprises at least one nucleic acid sequence according to claim 33, or a chimeric gene comprising a coding sequence as well as heterologous 5' and 3' regulatory sequences, which are able to function in a host organism, characterized in that the coding sequence comprises at least one nucleic acid sequence which encodes an SAT [according to one of claims 34 to 41]. --

Please amend claim 53 as follows:

-- **Claim 53.** (amended) Plant according to claim 52, characterized in that the plant is regenerated from a plant cell, and that it comprises at least one nucleic acid sequence encoding a transit peptide/SAT fusion protein, characterized in that the SAT is heterologous with the transit peptide [according to claim 51]. --

Claim 55, line 2, change "one of claims 52 to 54" to read -- claim 52 -- ;

Claim 56, line 2, change "one of claims 52 to 55" to read -- claim 52 -- ;

Claim 53, line 2, change "either of claims 56 and 57" to read -- claim 56 -- ;

Claim 59, line 2, change "one of claims 52 to 58" to read -- claim 52 -- .

R E M A R K S

The applicants respectfully request that this **Amendment** be entered prior to examination. **Claims 6, 12, 25, 27, 29, 33, 42, 45, 55-56 and 58-59** have been amended to refer to only one preceding claim. Support for **amended claim 24** can be found in the original claim 3; **amended claim 32** in the original claim 24; **amended claim 40** in original claim 2; **amended claim 41** in original claim 33; **amended claim 43** in original claim 34; **amended claim 44** in original claim 42; **amended claim 49** in original claim 34; **amended claim 50** in original claim 43; **amended claim 51** in original claim 34 and **amended claim 53** can be found in the original claim 51. Each of the dependent claims, as amended, now depends on only one preceding claim. Therefore no additional fee is required for multiple dependency.


Prompt, favorable action is solicited.

PH-98/080

Respectfully submitted,

CONNOLLY BOVE LODGE & HUTZ LLP

By



Robert G. McMorrow, Jr.
Registration No. 30,962
P.O. Box 2207
Wilmington, Delaware 19899
(302) 888-6268
Attorney for Applicants

RGMc/jm
(5500*42)

12/PRTS

02/486334
514 Rec'd PCT/PTO 22 FEB 2000

1

**Method for increasing the content of sulphur compounds
and in particular of cysteine, methionine and
glutathione in plants and plants obtained**

Methionine is the first limiting essential
5 amino acid in plants, in particular the leguminous
plants which are one of the basic elements of the
animal diet. Cysteine, another sulphur-containing amino
acid, is not an essential amino acid, but can be taken
to be a limiting element for animal nutrition since
10 cysteine is derived, in animals, from methionine. In
maize, the sulphur-containing amino acids are also
limiting amino acids after lysine and tryptophan. The
reason for this is that the major storage proteins of
the seeds of these plants are lacking in these amino
15 acids. The overproduction of methionine and cysteine in
the seeds of leguminous plants (soybean, lucerne, pea,
etc.) and of maize will thus have a considerable impact
on the nutritional quality of these seeds.

So far, the increase in the nutritional
20 quality of foods derived from the seeds of leguminous
plants has been obtained by supplementation with
chemically synthesized free methionine. For example,
the average contents of methionine + cysteine in
soybean and pea are of the order of 20 mg per g of
25 protein. This content must be increased to a value of
the order of 25 mg cysteine + methionine/g of protein
to cover the dietary needs of a human adult, and to a
value of the order of 48 mg of cysteine + methionine/g

of protein to cover those of pigs (De Lumen, B.O., Food Technology (1997) 51, 67-70).

The techniques for characterizing proteins enriched in sulphur-containing amino acids and the preparation of transgenic plants allowing the expression of such proteins, so as to increase the sulphur-containing amino acid content of these plants and thus their nutritive value for the animal diet, and thus to diminish the amount of synthesized methionine supplied, are now well known and described in the literature ([1] Korit, A.A. et al., Eur. J. Biochem (1991) 195, 329-334; WO 98/20133; WO 97/41239; WO 95/31554; WO 94/20828; WO 92/14822).

The enrichment in proteins with a high sulphur-containing amino acid content by such an approach remains, however, limited by the capacity of plant cells and of plants to produce the said sulphur-containing amino acids required for the synthesis of the protein. The reason for this is that plants overexpressing a protein rich in methionine and cysteine in their seed, such as for example lupins expressing 8S albumin, contain a level of free methionine and cysteine, and also of glutathione, which is lower than that of control plants ([2] Tabe, L. & Droux, M., 4th Workshop on Sulphur Metabolism, in press).

In the same way, peptides rich in sulphur-containing amino acids and having antifungal or

antibacterial activity have been identified
(WO 97/30082, WO 99/02717, WO 99/09184, WO 92/24594,
WO 99/53053). The expression of these peptides in the
plants makes it possible to increase the capacity of
5 the said plants to resist certain fungal or bacterial
attacks. Here again, the production of such peptides in
the plants remains limited by the capacity of plant
cells and plants to produce the sulphur-containing
amino acids required for the synthesis of these
10 peptides. The reason for this is that the expression of
these peptides in the plant cell occurs to the
detriment of the stock of glutathione, which is taken
to be a reservoir for cysteine.

It has been observed that the limiting
15 parameter of such an approach is indeed linked to this
capacity to produce methionine or cysteine. It is
therefore important to be able to modify in the plants
this capacity to produce methionine and cysteine in
sufficient quantities to allow the production of
20 heterologous proteins with a high sulphur-containing
amino acid content, that is to say to use a molecular
strategy intended to increase the levels of cysteine
and methionine in plants, and more particularly, crop
plants of agronomical interest.

25 In plants, methionine biosynthesis is carried
out from cysteine, this same cysteine being involved in
the synthesis of glutathione.

Glutathione is a form of storage of reduced sulphur and represents 60 to 70% of the organic sulphur in the cell. Glutathione plays an important role for plants in the resistance to oxidative stress and in the elimination of toxic compounds. It thus participates in the elimination of xenobiotic compounds: heavy metals (for example) via the formation of phytochelatins and metallothionines; herbicides, via glutathione S-transferase activity; which are toxic to the plant, and in the plant's defence mechanisms against micro-organisms. By increasing a plant's cysteine content, and consequently its glutathione content, it is thus possible to modulate the plant's response to the different stresses mentioned above.

There are therefore two distinct metabolic pathways starting from cysteine, one for the preparation of methionine, the other for the preparation of glutathione (**Figure 1**) and for which the different enzymes involved are recalled below. The SAT (E1) and OASTL (E2) activities are at a metabolic crossroads between the assimilation of organic nitrogen and carbon (serine) and of inorganic sulphur (reduced sulphur from the sequence of assimilation and reduction of sulphate, shaded box). The cysteine is then incorporated into proteins, but also participates in the synthesis of glutathione and methionine. The synthesis of the carbon backbone (O-phosphohomoserine) of this latter amino acid, is derived from aspartate.

5 (cystathionine γ -synthase) is indicated in the diagram

([3] Giovanelli J. in Sulphur Nutrition and Sulphur
Assimilation in Higher Plants, (1990) pp. 33-48;
[4] Chiba Y. et al. (1999), Science, 286, 1371-1374).

Methionine is the precursor of SAM

In plants the final steps of cysteine
15 synthesis involve the two enzymes below:

Serine + acetyl-coenzyme A \rightarrow O-acetylserine + coenzyme A

20 O-acetylserine + sulphide \rightleftharpoons cysteine + acetate

E3) cystathionine γ -synthase (EC 4.2.99.9) (CGS):

25 Pi signifies inorganic phosphate.

$$\text{cystathionine} + \text{H}_2\text{O} \rightleftharpoons \text{homocysteine} + \text{pyruvate} + \text{NH}_4^+$$

E5) methionine synthase (EC 2.1.1.14) (Ms) :

homocysteine + 5-methyltetrahydrofolate \rightleftharpoons methionine + tetrahydrofolate

As for the synthesis of glutathione from cysteine, it involves, successively, the two enzymes below:

E6) γ -glutamylcysteine synthetase (EC 6.3.2.2)

glutamate + L-cysteine + ATP \rightleftharpoons γ -glutamylcysteine + ADP + Pi

10 E7) glutathione synthetase (EC 6.3.2.3)

γ -glutamylcysteine + glycine + ATP \rightleftharpoons glutathione + ADP + Pi

All these enzymes have been characterized and cloned in plants ([5] Lunn, J.E. et al., *Plant Physiol.* (1990) 94, 1345-1352; [6] Rolland, N. et al., *Plant Physiol.* (1992) 98, 927-935; [7] Droux, M. et al., *Arch. Biochem. Biophys.* (1992) 295, 379-390; [8] Rolland, N. et al., *Arch. Biochem.* (1993) 300, 213-222; [9] Ruffet, M.L. et al., *Plant Physiol.* (1994) 104, 597-604; [10] Ravanel, S. et al., *Arch. Biochem. Biophys.* (1995) 316, 572-584; [11] Droux, M. et al., *Arch. Biochem. Biophys.* (1995) 316, 585-595; [12] Ruffet, M.L. et al., *Eur. J. Biochem.* (1995) 227, 500-509; [13] Ravanel, S. et al., *Biochem. J.* (1996) 320, 383-392; [14] Ravanel, S. et al., *Plant Mol. Biol.* (1996) 29, 875-882; [15] Rolland, N. et al., *Eur. J. Biochem.* (1996) 236, 272-282; [16] Ravanel, S. et al., *Biochem. J.* (1998) 331, 639-648; [17] Droux, M. et al.,

Eur. J. Biochem. (1998) 255, 235-245; [18] May, M.J.,
 Leaver, C.J., Proc. Natl. Acad. Sci. USA (1994) 91,
 10059-10063; [19] Ullmann, P. et al., Eur. J. Biochem.
 (1996) 236, 662-669; [20] Eichel, J. et al., Eur. J.
 5 Biochem. (1995) 230, 1053-1058).

It is known that for cysteine synthesis, the
 E1 and E2 enzymes are present in the three compartments
 of the plant cell, that is to say, the plasts, the
 cytosol and the mitochondria (5-6, 9, 12). These three
 10 E1 enzymes are named SAT2 and SAT4 for the (putative)
 chloroplast enzyme, and SAT1 for the mitochondrial
 enzyme, and SAT3 and SAT3' (SAT52) for the cytoplasmic
 enzyme. These localization attributions are based on
 sequence analysis.

15 For the methionine synthesis enzymes, the
 situation is different since the E3 and E4 enzymes are
 exclusively localized in the plasts (10-11, 13-14, 16),
 while the terminal E5 enzyme is in the cytosol (20).

As for the enzymes associated with the
 20 glutathione biosynthetic pathway, they are localized
 both in the chloroplast and in the cytosol ([21] Hell,
 R. and Bergmann, L., Planta (1990) 180, 603-612).

The E3 enzyme, of the methionine synthetic
 pathway, has a K_m (substrate concentration giving the
 25 half-maximal rate) of the order of 200 μ M to 500 μ M for
 cysteine (10, 16, [22] Kreft, B-D. et al., Plant
 Physiol. (1994) 104, 1215-1220).

The E6 enzyme, of the glutathione synthetic pathway, also has a high K_m for cysteine, of the order of 200 μ M [21].

It has now been observed the chloroplast
5 serine acetyltransferase enzyme (**Figure 2**) and to a
lesser degree the mitochondrial SAT are inhibited by
cysteine, in contrast to the cytoplasmic enzyme (**Figure**
2), this inhibition constituting the essential limiting
factor in the synthesis of cysteine in plant cells and
10 being downstream of the methionine and glutathione.

The present invention thus consists in
increasing the level of cysteine and methionine
synthesized in the cellular compartments of plant
cells, and in particular in the chloroplast
15 compartment. Increasing the level of cysteine, the
sulphur-containing precursor of glutathione and of
methionine and its derivatives, advantageously makes it
possible to increase the level of methionine and/or of
glutathione in the plant cells and plants, and
20 subsequently to improve the production of proteins,
natural or heterologous, enriched in sulphur-containing
amino acids in the plant cells and plants, and
similarly the tolerance of the plants to different
forms of glutathione-regulated stress.

25 This increase according to the invention is
obtained by overexpressing a serine acetyltransferase
(SAT) in the plant cells and plants.

The present invention thus relates to a method for increasing the production of cysteine, glutathione, methionine and sulphur-containing derivatives thereof, by plant cells and plants, the
 5 said method consisting in overexpressing an SAT in the plant cells and in plants containing the said plant cells.

The overexpressed SAT can consist of any SAT, whether of plant origin, in particular SAT2 or SAT4,
 10 SAT1, SAT3, SAT3' (SAT52), or of any other origin, in particular bacterial, in a native or mutant form or deleted of a fragment, and functional in the synthesis of O-acetylserine.

In particular, it can be a cysteine-sensitive
 15 SAT, such as for example a plant SAT, for example a chloroplast or mitochondrial SAT (SAT2, SAT4, SAT1), or a native SAT of bacterial origin ([22] Nakamori et al., 1998, Appl. Environ. Microbiol., 64, 1607-1611; [23] Takagi H. et al., 1999, Febs Lett. 452, 323-327;
 20 [24] Mino K. et al., 1999, Biosci. Biotechnol. Biochem., 63, 168-179).

It can also be a cysteine-insensitive SAT, such as, for example, a plant SAT, for example a cytoplasmic SAT (SAT3), or a mutant SAT of bacterial
 25 origin, made insensitive to cysteine by mutagenesis ([22] and [23], whose contents are incorporated here by reference), or any mutant plant SAT which is functional

in the synthesis of O-acetylserine (the carbon-containing precursor for cysteine synthesis).

According to a specific embodiment of the invention, the SAT is an *Arabidopsis thaliana* SAT [12].

5 According to a first embodiment of the invention, the SAT is overexpressed in the cytoplasm of the plant cells. The SAT is either a plant cytoplasmic SAT, in particular the SAT3 (L34076) or SAT3' or SAT52 (U30298), represented by the SEQ ID NO 1 or the SEQ ID
10 NO 2, respectively, or an SAT of bacterial origin as defined above. The SAT overexpressed in the cytoplasm can also be a noncytoplasmic plant SAT, for example a chloroplast or mitochondrial SAT. These noncytoplasmic plant SATs, naturally, are expressed in the cytoplasm
15 in the form of a precursor protein comprising a signal for addressing to the cellular compartment, other than the cytoplasm, into which the mature functional SAT is released. In order to overexpress these mature functional SATs in the cytoplasm, their addressing
20 signal is removed. In this case, the SAT protein overexpressed in the cytoplasm is a noncytoplasmic plant SAT, with its signal(s) for addressing to cellular compartments, other than the cytoplasm, removed.

25 According to a specific embodiment of the invention, the noncytoplasmic SAT with its addressing signal removed is SAT1' represented by SEQ ID NO 3.

According to a second embodiment of the invention, the SAT is overexpressed in the mitochondria. The protein is advantageously expressed in the cytoplasm in the form of a signal peptide/SAT fusion protein, the mature functional SAT being released inside the mitochondria. Advantageously, the mitochondrial addressing signal peptide is made up of at least one mitochondrial addressing signal peptide from a plant protein which is located in mitochondria, such as the tobacco ATPase β -F1 subunit signal peptide [[25] Hemon P. et al. 1990, Plant Mol. Biol. 15, 895-904], or the SAT1 signal peptide represented by amino acids 1 to 63 in SEQ ID NO 4.

According to a specific embodiment of the invention, the mitochondrial SAT is SAT1 (U22964) represented by SEQ ID NO 4.

According to a third embodiment of the invention, the SAT is overexpressed in the chloroplasts of the plant cells.

The SAT will be expressed in the chloroplasts by any appropriate means, in particular by any means known to persons skilled in the art and widely described in the prior art.

According to a specific embodiment of the invention, the SAT is overexpressed in the chloroplasts by integrating into the chloroplast DNA a chimeric gene comprising a DNA sequence encoding the said SAT, under the control of 5' and 3' regulatory elements that

function in the chloroplasts. The techniques for insertion of genes into chloroplasts, such as the regulatory elements appropriate for the expression of the said genes in chloroplasts, are well known to
5 persons skilled in the art and in particular are described in the following patents and patent applications: US 5,693,507, US 5,451,513 and WO 97/32977.

According to another specific embodiment of
10 the invention, the SAT is overexpressed in the cytoplasm in the form of a transit peptide/SAT fusion protein, the function of the transit peptide being to address the SAT to which it is fused to the chloroplasts, the mature functional SAT being released
15 inside the chloroplasts after cleavage at the chloroplast membrane.

In this case, the SAT can be a chloroplast SAT of plant origin, such as SAT2 or SAT4, represented by SEQ ID NO 5 or 6, respectively.

20 The SAT can also be a cytoplasmic SAT of plant origin or an SAT of bacterial origin as defined above. The cytoplasmic SATs are understood to include also noncytoplasmic SATs from which have been removed their signal for addressing to a compartment other than
25 the cytoplasm, as defined above.

The transit peptides, their structures, their methods of functioning and their use in the construction of chimeric genes for addressing a

heterologous protein into chloroplasts, as well as chimeric transit peptides comprising several transit peptides, are well known to persons skilled in the art and widely described in the literature. In particular,
5 the following patent applications are mentioned:
EP 189 707, EP 218 571 and EP 508 909, and the references cited in these patent applications, whose contents are incorporated here by reference.

In the fusion protein according to the
10 invention, the SAT can be homologous or heterologous to the transit peptide. In the first case, the fusion protein is the SAT2 or the SAT4 protein expressed naturally in the chloroplasts of plant cells. In the second case, the transit peptide can be a transit
15 peptide from an SAT2, represented by amino acids 1 to 32 of SEQ ID 5, or the transit peptide from an SAT4, represented by amino acids 1 to 30 of SEQ ID NO 6, or alternatively a transit peptide from another protein, which is located in plastids, in particular the transit
20 peptides defined below. Plastid localization protein is understood to mean a protein expressed in the cytoplasm of plant cells in the form of a transit peptide/protein fusion protein, the mature protein being localized in the chloroplast after cleavage of the transit peptide.

25 A plant EPSPS transit peptide is, in particular, described in Patent Application EP 218,571, while a plant RuBisCO ssu transit peptide is described in Patent Application EP 189,707.

According to another embodiment of the invention, the transit peptide also comprises, between the C-terminal region of the transit peptide and the N-terminal region of the SAT a portion of sequence from the mature N-terminal region of a plastid localization protein, this portion of sequence generally comprising less than 40 amino acids from the N-terminal region of the mature protein, preferably less than 30 amino acids, more preferably between 15 and 25 amino acids.

Such a transit peptide comprising a transit peptide fused to a part of the N-terminal region of a plastid localization protein is, in particular, described in Patent Application EP 189,707, more particularly for the transit peptide and the N-terminal region of plant RuBisCO ssu.

According to another embodiment of the invention, the transit peptide also comprises, between the C-terminal region of the N-terminal region of the mature protein and the N-terminal region of the SAT, a second transit peptide from a plastid localization plant protein. Preferably, this chimeric transit peptide comprising a combination of several transit peptides, is an optimized transit peptide (OTP) made by fusing a first transit peptide with a portion of sequence from the mature N-terminal region of a protein which is located in plastids, which is fused with a second transit peptide. Such an optimized transit peptide is described in Patent Application EP 508,909,

more particularly, the optimized transit peptide comprising the sunflower RuBisCO ssu transit peptide fused to a peptide made of the 22 N-terminal amino acids of the mature maize RuBisCO ssu, fused to the
5 maize RuBisCO ssu transit peptide.

The present invention also relates to a transit peptide/SAT fusion protein in which the SAT defined above is heterologous to the transit peptide and in which the transit peptide is made of at least
10 one transit peptide from a natural plant protein which is located in plastids, as defined above.

The present invention also relates to a nucleic acid sequence encoding a transit peptide/SAT fusion protein, described above. According to the
15 present invention, "nucleic acid sequence" is understood to mean a nucleotide sequence which can be of DNA or RNA type, preferably of DNA type, in particular double-stranded, whether of natural or synthetic origin, in particular a DNA sequence in which
20 the codons encoding the fusion protein according to the invention have been optimized according to the host organism in which it will be expressed, these optimization methods being well known to persons skilled in the art.

25 A subject of the invention is also the use of a nucleic acid sequence encoding an SAT according to the invention defined above, in particular for chloroplast, mitochondrial or cytoplasmic addressing,

in a method for transforming plants, as a coding sequence allowing the modification of the cysteine, methionine, methionine derivatives, and glutathione contents of the transformed plants. This sequence can
 5 of course also be used in combination with other marker gene(s) and/or coding sequence(s) for one or more other agronomic properties.

The present invention also relates to a chimeric gene (or expression cassette) comprising a
 10 coding sequence as well as heterologous 5' and 3' regulatory elements capable of functioning in a host organism, in particular plant cells or plants, the coding sequence comprising at least one nucleic acid sequence encoding an SAT as defined above.

15 Host organism is understood to mean any monocellular or pluricellular higher or lower organism, into which the chimeric gene according to the invention can be introduced. They are in particular bacteria, for example *E. coli*, yeasts, in particular of the genera
 20 *Saccharomyces*, *Kluyveromyces* or *Pichia*, fungi, in particular *Aspergillus*, a baculovirus, or preferably plant cells and plants.

"Plant cell" is understood to mean according to the invention any cell derived from a plant and
 25 capable of constituting undifferentiated tissues such as calli, differentiated tissues such as embryos, plant portions, plants or seeds.

"Plant" is understood to mean according to the invention any differentiated multicellular organism capable of photosynthesis, in particular monocotyledonous or dicotyledonous plants, more particularly crop plants intended or not as animal feed or for human consumption, such as maize, wheat, rape, soybean, rice, sugar cane, beet, tobacco, cotton and the like.

The regulatory elements required for the expression of the a nucleic acid sequence encoding a fusion protein according to the invention are well known to persons skilled in the art according to the host organism. They comprise, in particular, promoter sequences, transcription activators, termination sequences including start and stop codons. The means and methods of identifying and selecting the regulatory elements are well known to persons skilled in the art and widely described in the literature.

The invention relates more particularly to the transformation of plants. Promoter regulatory sequences which can be used in plants, are any promoter sequence of a gene which is naturally expressed in plants, in particular a promoter which is expressed in particular in the leaves of plants such as, for example, so-called constitutive promoters of bacterial, viral or plant origin, or alternatively so-called light-dependent promoters such as that of a plant ribulose-biscarboxylase/oxygenase (RuBisCO) small

5

10

20

Regulatory termination or polyadenylation sequences which can be used, are any corresponding

sequence of bacterial origin, such as for example the
nos terminator of *Agrobacterium tumefaciens*, or
alternatively of plant origin, such as for example a
histone terminator as described in Application
5 EP 0,633,317.

The present invention also relates to a
cloning and/or expression vector for the transformation
of a host organism containing at least one chimeric
gene as defined above. This vector comprises, besides
10 the chimeric gene above, at least one origin of
replication. This vector can be a plasmid, a cosmid, a
bacteriophage or a virus, which has been transformed by
introducing a chimeric according to the invention. Such
transformation vectors, according to the host organism
15 to be transformed, are well known to persons skilled in
the art and widely described in the literature. For the
transformation of plant cells or plants, a virus,
moreover containing its own elements of replication and
expression, can, in particular, be used to transform
20 developed plants. Preferably, the transformation vector
of plant cells or plants according to the invention is
a plasmid.

For the transformation of host organisms, the
chimeric gene according to the invention can be used in
25 combination with a selection marker gene, either in the
same vector, the two genes being combined in a
convergent, divergent or colinear manner, or
alternatively in two vectors used simultaneously for

transforming the host organism. Such marker genes and their use for transforming host organisms are well known to persons skilled in the art and widely described in the literature.

- 5 Among genes encoding selection markers which can be mentioned are antibiotic-resistance genes, genes which impart tolerance to herbicides (bialaphos, glyphosate or isoxazoles), genes encoding easily identifiable enzymes such as the GUS enzyme (or GFP,
- 10 "Green Fluorescent Protein"), or genes encoding pigments or enzymes which regulate the production of pigments in the transformed cells. Such selection marker genes are in particular described in Patent Applications EP 242 236, EP 242 246, GB 2 197 653,
- 15 WO 91/02071, WO 95/06128, WO 96/38567 or WO 97/04103.

 The subject of the invention is also a method for transforming host organisms, in particular plant cells, by integration of at least one nucleic acid sequence or one chimeric gene as defined above, which

20 transformation may be obtained by any known appropriate means, widely described in the specialist literature and in particular the references cited in the present application, more particularly by the vector according to the invention.

- 25 One series of methods consists in bombarding cells, protoplasts or tissues with particles to which the DNA sequences are attached. Another series of methods consists in using, as a means of transferring

into the plant, a chimeric gene inserted into an *Agrobacterium tumefaciens* Ti plasmid or an *Agrobacterium rhizogenes* Ri plasmid. Other methods can be used, such as microinjection or electroporation, or
5 alternatively direct or PEG precipitation. Persons skilled in the art will choose the appropriate method according to the nature of the host organism, in particular of the plant cell or of the plant.

The subject of the present invention is also
10 the host organisms, in particular plant cells or plants, which are transformed and which contain a chimeric gene defined above.

The subject of the present invention is also the plants containing transformed cells, in particular
15 the plants regenerated from the transformed cells. The regeneration is obtained by any appropriate method which depends on the nature of the species, as for example described in the above references. Patents and patent applications which are mentioned for the methods
20 of transforming plant cells and of regenerating plants are, in particular, the following: US 4,459,355, US 4,536,475, US 5,464,763, US 5,177,010, US 5,187,073, EP 267,159, EP 604,662, EP 672,752, US 4,945,050, US 5,036,006, US 5,100,792, US 5,371,014, US 5,478,744,
25 US 5, 179,022, US 5,565,346, US 5,484,956, US 5,508,468, US 5,538,877, US 5,554,798, US 5,489,520, US 5,510,318, US 5,204,253, US 5,405,765, EP 442,174,

EP 486,233, EP 486,234, EP 539,563, EP 674,725,
WO 91/02071 and WO 95/06128.

The subject of the present invention is also
the transformed plants derived from the cultivation
5 and/or the crossing of the above regenerated plants, as
well as the seeds of the transformed plants.

The transformed plants which can be obtained
according to the invention can be of monocotyledonous
type, such as for example cereals, sugar cane, rice and
10 maize, or of dicotyledonous type, such as for example
tobacco, soybean, rape, cotton, beet, clover, etc.

The plants transformed according to the
invention can contain other genes of interest, which
confer novel agronomic properties on the plants. Among
15 genes conferring novel agronomic properties on the
transformed plants which can be mentioned are genes
conferring tolerance to certain herbicides, those
conferring tolerance to certain insects, and those
conferring tolerance to certain diseases. Such genes
20 are in particular described in Patent Applications
WO 91/02071 and WO 95/06128. Mention may also be made
of genes which modify the composition of the modified
plants, in particular the content and quality of
certain essential fatty acids (EP 666,918), or
25 alternatively the content and quality of proteins, in
particular in the leaves and/or seeds of the said
plants. In particular, genes encoding proteins enriched
in sulphur-containing amino acids are cited([1];

WO 98/20133; WO 97/41239; WO 95/31554; WO 94/20828;
WO 92/14822; US 5,939,599, US 5,912,424). The function
of these proteins enriched in sulphur-containing amino
acids is also to trap and store surplus cysteine and/or
5 methionine, making it possible to avoid any problems of
toxicity linked to an overproduction of these sulphur-
containing amino acids, by trapping them.

Mention may also be made of genes encoding
peptides rich in sulphur-containing amino acids and
10 more particularly rich in cysteine, the said peptides
also having antibacterial and/or antifungal activity.
More particularly, plant defensins are mentioned, as
well as lytic peptides of any origin, and more
particularly the following lytic peptides: androctonin
15 (WO 97/30082 and WO 99/09189), drosamicin
(WO 99/02717), thanatin (WO 99/24594) or heliomicin
(WO 99/53053).

These other genes of interest can be combined
with the chimeric gene according to the invention
20 either by conventional crossing of two plants each
containing one of the genes (the first being the
chimeric gene according to the invention and the second
being the gene encoding the protein of interest), or by
transforming the plant cells of a plant containing the
25 gene encoding the protein of interest, with the
chimeric gene according to the invention.

The following examples illustrate the invention, without, however, looking to limit its scope.

All of the methods or operations described below in these examples are given by way of examples and correspond to a choice made from the different methods available to arrive at the same result. This choice has no bearing on the quality of the result and consequently, any adapted method can be used by persons skilled in the art to arrive at the same result. Most of the methods for engineering DNA fragments are described in "Current Protocols in Molecular Biology" Volumes 1 and 2, Ausubel F.M. et al, published by Greene Publishing Associates and Wiley Interscience (1989) or in Molecular Cloning, T. Maniatis, E.F. Fritsch, J. Sambrook, 1982.

The contents of all the references cited in the above description and in the following examples are incorporated into the text of the present patent application by reference.

Example 1. Demonstration of the inhibition of chloroplast serine acetyltransferase from pea (*Pisum sativum*) leaves by cysteine

The three subcellular compartments corresponding to the cytosol (preparation from a subcellular fractionation of pea protoplasts, [12]), to mitochondria and to chloroplasts are prepared from pea

leaves [12]. The soluble proteins are extracted therefrom and the serine acetyltransferase activity present in each of the compartments is measured by means of a described technique [12, 17].

5

Description of the assay method:

The serine acetyltransferase activity is measured by high performance liquid chromatography (HPLC), by assaying the O-acetylserine formed during
10 the course of the reaction (reaction 1), after derivatization with orthophthalaldehyde (OPA). A defined quantity of the protein extract, corresponding to the cytosol and to the different soluble fractions of chloroplasts (stroma) and of mitochondria (matrix),
15 is desalted on a PD10 column (Pharmacia) pre-equilibrated in a buffer containing 50 mM Hepes-HCl, pH 7.5 and 1 mM EDTA. The enzyme reaction is carried out in the presence of 50 mM Hepes-HCl, pH 7.5, 1 mM dithiothreitol, 10 mM L-serine, 2.5 mM acetyl-CoA, in a
20 100 µl reaction volume, at 25°C. After 10 to 15 minutes' incubation, the reaction is stopped by addition of 50 µl of 20% (W/V) trichloroacetic acid. The proteins thus precipitated are then eliminated by centrifugation for 2 min at 15,000 g. The supernatant,
25 which contains the reaction product (OAS), is mixed with 500 µl of a derivatization solution (54 mg of OPA dissolved in 1 ml of absolute ethanol, 9 ml of a 400 mM solution of borate-NaOH, pH 9.5, and 0.2 ml of 14 M

β -mercaptoethanol) and incubated for 2 min. A fraction of this mixture (20 μ l) is injected onto a reverse phase column (3.9 \times 150 mm, AccQ Tag C₁₈ column, Waters) which is connected to an HPLC system. The buffers used to elute the compounds derivatized by OPA are: Buffer A, 85 mM sodium acetate, pH 4.5 and 6% (V/V) acetonitrile, pH 4.5; Buffer B, 60% (V/V) acetonitrile in water. The *O*-acetylserine, which has been derived by OPA, is eluted with a continuous linear gradient of buffer B in buffer A, of 25 to 70% (V/V), and is detected by fluorescence at 455 nm (excitation at 340 nm). The retention time of *O*-acetylserine, under our conditions, is of the order of 6.2 min., and the amount of product which is formed in the enzyme assays is quantified from a standard curve which is obtained for *O*-acetylserine. The enzyme assays were optimized in order to respect the optimum pH of the reaction, the linearity with time, and in order to operate under saturating conditions of substrates.

20

Effect of cysteine on serine acetyltransferase activity of pea leaves

Incubation (2 min) is carried out in the presence of protein extract (cytosol, matrix, and stroma), and in the presence of increasing concentrations of L-cysteine (from 0 to 1 mM), before adding saturating concentrations of the serine acetyltransferase substrates, L-serine (10 mM) and

acetyl-CoA (2.5 mM). The enzyme reaction and assay of residual O-acetylserine in the supernatant are carried out as described above. The result of these experiments is represented in the graph of **Figure 2**, in the annex.

- 5 If free cysteine (from 0 to 1 mM, **Figure 2**) is added to the different assays, a very strong inhibition of chloroplast serine acetyltransferase activity is observed (inhibition constant of the order of 30 μ M). Mitochondrial serine acetyltransferase
- 10 activity is inhibited, but at higher concentrations of cysteine (inhibition constant of the order of 300 μ M). On the other hand, cytosolic serine acetyltransferase activity is insensitve to inhibition by cysteine up to concentrations of the order of 1 mM cysteine
- 15 (**Figure 2**). This result proves, therefore, that only chloroplast serine acetyltransferase activity, thus the enzyme associated with the sulphate assimilation pathway, is inhibited by the final product, L-cysteine.

Table I: Determination of the specific activities and IC₅₀ values of cysteine for each of the serine acetyltransferase isoforms.

| Serine acetyltransferase (<i>Pisum sativum</i>) | | |
|--|--|--|
| | Specific activity nmol OAS·min⁻¹·mg⁻¹ | IC₅₀ L-cysteine μM |
| Stroma | 0.93 ± 0.2 | 33.4 ± 8 |
| Matrix | 10 ± 2 | 283 ± 50 |
| Cytosol | 0.83 ± 0.3 | no inhibition |

5

The concentration of L-cysteine which makes it possible to obtain 50% inhibition (IC₅₀) under standard reaction conditions, and which is calculated for different enzyme preparations, is represented in

10 Table I. Determination of the serine acetyltransferase enzyme activity and of the IC₅₀ is carried out for 9 different experiments (on stroma), and for 3 experiments for the cytosolic extracts and 3 for the mitochondrial extracts. Similarly, activity of

15 chloroplast serine acetyltransferase from spinach leaves is cysteine-sensitive. Conversely, in *Arabidopsis thaliana*, only the activity of the isoform associated with the cytosolic compartment seems to be controlled by the level of cysteine ([27] Noji M. et

20 al. 1998, J. Biol. Chem. 273, 32739-32745; [28] Inoue K. et al. 1999, Eur. J. Biochem. 266, 220-227). For

these authors, the activity associated with the chloroplast compartment is cysteine-insensitive. It would seem, therefore, that inhibition of the chloroplast serine acetyltransferase activity by cysteine is a plant-specific phenomenon, but, in particular, is very pronounced in leguminous plants, such as pea.

Study of the mode of inhibition of serine

10 acetyltransferase activity by cysteine

The enzyme reaction rate was determined for fixed concentrations of cysteine (0 μM ; 10 μM ; 20 μM ; 40 μM ; 60 μM and 100 μM), by varying either the L-serine concentration or the acetyl-CoA concentration, for saturating concentrations of the second co-substrate. For each of the kinetics obtained, the affinity of the enzyme for these substrates does not seem to be affected, but, on the other hand, the maximum reaction rate is modified. The more the concentration of L-cysteine increases, the more the rate of O-acetylserine synthesis decreases. For each of the conditions analysed, the inhibition constant K_i was estimated to be of the order of 30 (± 2.2) μM (variable substrate: serine), and 22 (± 2) μM (variable substrate: acetyl-CoA). We were able to show that cysteine is a non-competitive type of inhibitor of serine acetyltransferase activity and that, moreover, it is an allosteric type inhibitor (Hill constant of the order

of $1.6 \pm 0.3 \mu\text{M}$), using conventional kinetics equations ([29] Segel, I.H. (1995), John Wiley and Sons, New York). These results indicate that inhibition of the chloroplast enzyme takes place at a site other than the active site, which moreover, does not exist in the serine acetyltransferase isoform which is present in the cytosol.

These inhibition constants are consistent with the cysteine concentration determined for pea chloroplasts of $40 \pm 10 \mu\text{M}$ (2 nmol/mg chlorophyll), a value which is calculated for a stromal compartment volume of the order of 35 to 65 μl per mg of chlorophyll.

15 **Dissociation of the bi-enzymatic complex, cysteine synthase, by cysteine**

The serine acetyltransferase of the plant cell, like its bacterial homologue, forms an enzymatic complex with *O*-acetylserine (thiol) lyase, the enzyme which catalyses the condensation of reduced sulphur with *O*-acetylserine. This bi-enzymatic complex is called cysteine synthase. All of the serine acetyltransferase of the chloroplast exists in a form complexed with *O*-acetylserine (thiol) lyase, while the majority of the *O*-acetylserine (thiol) lyase is in the free form. The distribution of each of these enzymes in each of the subcellular compartments of pea leaves is described in Table II.

Table II: Specific activity of serine acetyltransferase and O-acetylserine (thiol) lyase activities in the cellular compartments of pea leaves

| | Serine acetyl- transferase | O-acetylserine (thiol) lyase | |
|----------------|-------------------------------|---------------------------------|-----------------|
| | Specific activity (mU/mg) | | OASTL/SAT Ratio |
| Stroma | 0.85 | 260 | 306 |
| Matrix | 12 | 50 | 4 |
| Cytosol | 0.90 | 180 | 200 |

5

The ratio of O-acetylserine (thiol) lyase (OASTL) activity to serine acetyltransferase (SAT) activity reflects the large excess of OASTL over SAT. In particular in the stroma (chloroplast), where the

10 assimilation and reduction of sulphate takes place, and in the cytosol, 95% of the OASTL activity is in the free form. These conditions are necessary for optimal synthesis of cysteine [14]. The cysteine synthase complex is composed of a serine acetyltransferase

15 tetramer and two O-acetylserine (thiol) lyase dimers. O-Acetylserine, the reaction product of serine acetyltransferase, dissociates this bienzymatic complex, and sulphur tends to stabilize it [14]. These

20 protein-protein interactions within the complex confer novel properties on each of the enzymes; in particular serine acetyltransferase acquires novel catalytic

properties compared to the free form. Moreover, complexed *O*-acetylserine (thiol) lyase is inactive in cysteine synthesis, and only the free form (in excess in the cell) catalyses cysteine synthesis [14].

5 A chloroplast (*Pisum sativum*) fraction, pre-incubated in the presence of an optimal concentration of cysteine (0.1 mM), which inhibits serine acetyltransferase (see Figure 2), then undergoes gel filtration chromatography which allows the separation
10 of molecules according to their molecular mass. Under these conditions the cysteine synthase complex dissociates into serine acetyltransferase tetramers and *O*-acetylserine (thiol) lyase dimers. Chloroplast serine acetyltransferase in its free form is still sensitive
15 to inhibition by cysteine. To refine this result and to confirm that inhibition of the enzyme is not dependent upon interaction with OASTL, a serine acetyltransferase was partially purified from pea chloroplasts, by ion exchange chromatography followed by molecular
20 filtration chromatography carried out in the presence of *O*-acetylserine (1 mM), a condition which leads to dissociation of the complex.

The serine acetyltransferase fraction thus free of contamination by *O*-acetylserine (thiol) lyase
25 is incubated in the presence of increasing concentrations of cysteine under the conditions described in Table I and **Figure 2**. The calculated IC₅₀ is of the order of 15 +/- 3 micromolar and is

comparable to the value obtained above for the enzyme under chloroplast conditions (see Table I). This latter result makes it possible to establish a model to explain the inhibition of chloroplast serine acetyltransferase. In **Figure 3**, the tetrameric form of serine acetyltransferase (SAT) is depicted by the grey circles and the O-acetylserine (thiol) lyase (OASTL) dimer by the black circles. The functional cysteine synthase complex in the cell is depicted by the combination of the two molecular populations. In the presence of cysteine, the cysteine synthase complex binds cysteine, which modifies the protein-protein interactions within the cysteine synthase complex, and leads to dissociation into SAT tetramers and OASTL dimers. The SAT thus in its free form is therefore sensitive to cysteine, and it is known that this structure has a tendency to form aggregates (apart from the cysteine synthase complex) whose effect is to cause a loss of its activity [14].

20

Example 2. Isolation and characterization of a gene encoding a putative cytoplasmic serine acetyltransferase isoform (SAT3) [12]

In this example the procedure described on page 502 of Ruffet et al. [12], is taken up, in particular the chapters described under the headings "Bacterial strain and growth conditions" and "Isolation

of *A. thaliana* serine acetyltransferase cDNA clones by complementation in *E. coli*".

A gene encoding a putative cytosolic serine acetyltransferase (Z34888 or L34076) represented in **Figure 4** (SEQ ID NO 1), was isolated by functional complementation of an *Escherichia coli* strain deficient in serine acetyltransferase activity. Analysis of the primary sequence showed the presence of strong similarity with the sequence of the bacterial enzyme (56% homology and 41% identity).

The following primers were used to amplify the nucleotide sequence and to clone it into the vector used for transforming tobacco plants:

Oligo 1: 5'GAGAGAGGAT CCTCTTTCCA ATCATAAACCATGGCAACATGCATAGACAC ATGC 3'
Oligo 2: 5'GGCTCACCAG ACTAATACAC TAAATTGTGT TTACCTCGAGAGAGAG 3'

These primers make it possible to introduce a 5' *Bam*H1 restriction site (GGATCC) and a 3' *Sac*I restriction site (GAGCTC).

The N terminus of the amino acid sequence of the SAT3 isoform does not have the characteristics of organelle (mitochondrion or chloroplast) addressing peptides. This analysis leads to the assumption that this isoform is located in the cytosol [12]. The absence of an addressing peptide of chloroplast type in this isoform was confirmed in chloroplast import experiments ([29] Murillo et al. 1995, Cell. and Mol.

Biol. Research 41, 425-433). Conversely, a study using constructs which include a portion of the nucleotide sequence and a marker protein (Green Fluorescent Protein, GFP) showed the presence of the fusion product (5'-SAT3-GFP) in the chloroplast of transformed *A. thaliana* plants (vegetative stage of the plant) and also in the cytosol (at the floral stage)[27].

The SAT3 gene (L34076) contains no introns.

10 **Example 3. Overexpression and purification of SAT3 in *Escherichia coli***

The defined protocol for overexpression of the enzyme in *E. coli* makes it possible to purify the enzyme in its free form or complexed with plant O-acetylserine (thiol) lyase, the cysteine synthase complex [14]. Using the purified proteins, the effect of cysteine on serine acetyltransferase activity was analysed by a spectrophotometric assay based on the consumption of acetyl-CoA during reaction 1, as a function of incubation time. This analysis is carried out in a medium (1 ml) containing 50 mM Hepes-HCl, pH 7.5, 2 mM L-serine and 0.2 mM acetyl-CoA. The reaction is followed by measuring the decrease in absorbance at 232 nm (molecular extinction coefficient of 4200 M⁻¹cm⁻¹) ([30] Kredich, N.M. et al., J. Biol. Chem. (1969) 244, 2428-2439). We were able to show that this isoform (SAT3) in its free form or complexed with O-acetylserine (thiol) lyase, is cysteine-insensitive.

This result allows us to confirm that this cDNA (L34076, **Figure 4**) encodes a cytosolic serine acetyltransferase, since the amino acid composition of the N-terminus does not have the characteristics of transit peptides, and moreover, since this serine acetyltransferase is cysteine-insensitive. This latter result is similar to observations which have been obtained for the cytosolic serine acetyltransferase activity of pea leaves (**Figure 2** and Table I).

10

Example 4. Isolation and characterization of a gene encoding a cytoplasmic serine acetyltransferase isoform (SAT3') (U30298)

The procedure of Example 3 is repeated, using oligonucleotides 3 and 4 below:

Oligo 3: 5'GAGAGAGGAT CCTCTTATCG CCGCGTTAAT ATGCCACCGG
CCGGAGAACTC C 3'

Oligo 4: 5'GAGCCTTACC AGTCTAATGT AGTATATTTC AACCTCGAGA
GAGAG 3'

A gene is isolated which encodes an acetyltransferase (U 30298), and is represented in **Figure 5** (SEQ ID NO 2). Analysis of the primary

sequence showed the presence of strong similarity with the sequence of the bacterial enzyme (51.6% homology and 42.6% identity). The N-terminal structure (absence of the conditions necessary for organelle addressing) indicates that this isoform is located in the cytosol. On the other hand, it is given as being cysteine-

sensitive [27]. This result differs from the data obtained from pea leaves (and from spinach leaves), in the sense that the cysteine regulation site seems to be confined to the cytosol in *A. thaliana* [27]. Moreover, it would seem that *A. thaliana* has at least two cytosolic isoforms: SAT3 (Example 3) and SAT3' (or U30298, Example 4). Unlike the SAT3 gene, the gene corresponding to **SAT3'** has an intron.

10 **Example 5. Isolation and characterization of genes encoding a serine acetyltransferase isoform (SAT1')**

The procedure described in Example 3 is repeated for the present example.

A gene encoding a serine acetyltransferase (L78443), which is represented in **Figure 6** (SEQ ID NO 3), was isolated by functional complementation of an *Escherichia coli* strain deficient in serine acetyltransferase activity [12]. Analysis of the primary sequence shows strong similarity with the sequence of the bacterial enzyme (52.7% homology and 39% identity).

The following primers were used to amplify the nucleotide sequence and to clone it into the vector which is used for transforming tobacco plants (in bold characters in **Figure 3**):

Oligo 5: 5'GAGAGAGGAT CCGCTCCTCC TCCTCCTCCT ATGGCTGCGT
GCATCGACAC CTG 3'

Oligo 6: 5'GCTCACCAGC CTAATACATT AAACCTTTTTC AGCTCGAGAG
AGAG 3'

These primers make it possible to introduce a
5' *Bam*H1 restriction site (GGATCC) and a 3' *Sac*I
restriction site (GAGCTC).

5 A second gene is obtained which encodes a
putative mitochondrial serine acetyltransferase
(U22964), and is represented in **Figure 7** (SEQ ID NO 4),
by repeating the same procedure, using oligo 7 to
replace oligo 5 as the 5' primer.

10 Oligo 7°: 5'GAGAGAGGAT CCGGCCGAGA AAAAAAAAAA ATGTTGCCGG
TCACAAGTCG CCG 3'

The N-terminus of the amino acid sequence of
the SAT1 isoform has the characteristics of organelle
(mitochondrion or chloroplast) addressing peptides.
Localization in the mitochondrion was recently
15 confirmed by constructing a fusion protein which
includes the 5' portion and "green fluorescent protein"
(5'SAT1-GFP) and by transforming *Arabidopsis thaliana*
plants [27]. Neither the SAT1' gene (L78443) nor the
SAT1 gene (U22964), like its homologue (SAT3), has
20 introns.

Example 6. Overexpression and purification of SAT1 in *Escherichia coli*. Localization of this isoform in *A. thaliana*

The defined protocol for overexpression of the enzyme in *E. coli* makes it possible to purify the enzyme (in its transit peptide-lacking form, SAT L78443) in its free form or complexed with plant *O*-acetylserine (thiol) lyase, the cysteine synthase complex [14]. Using the purified proteins, the effect of cysteine on serine acetyltransferase activity was analysed by spectrophotometric assay, based on the consumption of acetyl-CoA during reaction 1, as a function of incubation time (see Example 3). Analysis was also carried out by HPLC assay of the reaction product (OAS) (see Example 1). We were able to show that this isoform (SAT1'), in its free form or complexed with *O*-acetylserine (thiol) lyase, is cysteine-insensitive. This latter result parallels the observations obtained for pea leaf mitochondrial serine acetyltransferase activity (**Figure 2** and Table I), the latter being inhibited at non-physiological concentrations of cysteine.

Using a preparation of mitochondria obtained from pea leaves or from protoplasts from cell cultures, localization in the mitochondrion was confirmed for this isoform.

A mitochondrial fraction lacking in plastid and in cytosolic contaminants was obtained by using the

protocol defined for pea leaf mitochondria [12]. The molecular mass of the polypeptide as revealed by antibodies raised against the peptide [-TKTLHTRPLLEDLDR-] (see SAT1 amino acid sequence), is
 5 of the order of 34,000 daltons, a value which is in agreement with the mass of the protein as obtained using sequence analysis programs for predicting cleavage sites.

10 **Example 7. Isolation and characterization of genes encoding a serine acetyltransferase isoform (SAT2)**

The procedure described for Example 3 is repeated for the present example.

A gene which encodes a serine
 15 acetyltransferase (L78444), represented in **Figure 8** (SEQ ID NO 5), was isolated by functional complementation of an *Escherichia coli* strain deficient in serine acetyltransferase activity [12]. Analysis of the primary sequence showed the presence of strong
 20 similarity with the sequence of the bacterial enzyme (49.5% homology and 35.4% identity).

The following primers were used to amplify the nucleotide sequence and to clone it into the vector which was used to transform tobacco plants (in bold
 25 characters in **Figure 8**):

Oligo 8 : 5'GAGAGAGGAT CCGACAAGTT GGCATAATTT
ATGGTGGATC TATCTTCCT 3'

Oligo 9 : 5'CCTGTGTGAT TGTCGTGTAG TACTCTAGAA
ACTCGAGAGA GAG 3'

These primers make it possible to introduce a 5' *Bam*H1 restriction site (GGATCC) and a 3' *Sac*I restriction site (GAGCTC).

5 Analysis of the N-terminal portion of the sequence shows the presence of characteristics for addressing of the protein to an organelle (mitochondrion or chloroplast). Unlike the other isoforms described above, the SAT2 gene is complex and
10 has several introns. Comparing SAT2 sequences with its homologues from *A. thaliana*, from plants and from other organisms, leads to the assumption of a prokaryotic origin (**Figure 10**). Moreover, analysis of the N-terminal sequence using the chloroP program
15 [<http://www.cbs.dtu.dk/services/chlorP/>], indicates a high probability of the presence of a chloroplast-type transit peptide.

Example 8. Isolation and characterization of genes 20 encoding a serine acetyltransferase (SAT4) isoform

A gene which encodes a serine acetyltransferase (SAT4), represented in **Figure 9** (SEQ ID NO 6), was isolated by functional complementation of an *Escherichia coli* strain deficient in serine
25 acetyltransferase activity [12]. Analysis of the

primary sequence showed the presence of strong similarity with the sequence of the bacterial enzyme (44.5% homology and 32% identity).

The following primers were used to amplify the nucleotide sequence and to clone it into the vector which was used for transforming tobacco plants:

Oligo 10: 5' GAGAGAGGAT CCGACAAGTTGG CATAATTTAT GGCTTGTATA
AACGGCGAGA ATCGTGATTT TTCTT 3'

Oligo 11: 5' TACCTCGTAC CACTCAGAAC TCTAGAACT CGAGAGAGAG3'

These primers make it possible to introduce a 5' *Bam*HI restriction site (GGATCC) and a 3' *Sac*I restriction site (GAGCTC).

Analysis of the N-terminal portion sequence shows the presence of characteristics for addressing of the protein to an organelle (mitochondrion or chloroplast). The SAT4 gene, like that of SAT2, is complex and has several introns. Comparing SAT4 sequences with its homologues from *A. thaliana*, from plants and from other organisms, leads to the assumption of a prokaryotic origin (**Figure 10**).

Moreover, analysis of the N-terminal sequence using the chloroP program

[<http://www.cbs.dtu.dk/services/chlorP/>], indicates a high probability of the presence of a chloroplast-type transit peptide. **Figure 10** represents the sequence comparison and was carried out using the Clustaw

program (Vector NTI software). SAT2 and SAT4 are closer to the prokaryotic SATs than are SAT3, SAT1 and SAT52.

Moreover, the branch also comprises an SAT from red alga (AB00848), which has been identified as a cysteine-sensitive protein located in the chloroplast ([32] Toda et al., 1998, Biochim. Biophys. Acta 1403, 72-84). SAT4 is identified as being on chromosome 4 (Bac clone F8D20, access number AL031135).

Example 9. Constructs used for transforming tobacco plants of the small Havana variety

10 **Transgene expression in leaves**

Transformation of tobacco plants is carried out through *Agrobacterium tumefaciens* EHA105, which contains the pBI121 vector (Clontech) (**Figures 11 and 12**).

15 **SAT3 (or SAT1' or any cysteine-insensitive SAT)**

To obtain expression of the SAT3 (SEQ ID NO 1) of Example 2 in the chloroplast (**Figure 11**), an extension which allows addressing to this compartment is introduced 5' of the cDNA. For this, the optimized transit peptide previously described is used.

A kanamycin-resistance gene (NPTII) which encodes neomycin phosphotransferase, and which is used as a selection marker for transforming tobacco, is cloned between the left (LE) and right (RE) edges of the t-DNA. Expression of the NPTII gene is under the control of the promoter and of the terminator of *A. tumefaciens* nopaline synthase. Downstream, the

β -glucuronidase gene which has been cloned between the unique *Bam*H1 and the unique *Sac*I sites, is under the control of the cauliflower mosaic virus (CaMV) 35S promoter and the nopaline synthase gene polyadenylation signal from the Ti plasmid. The OTP-SAT3 construct is inserted between the *Xho* and *Sac*I sites of the vector, from which has been deleted the β -glucuronidase gene (Figure 11).

SAT1, SAT3, SAT3', SAT2, SAT4 or any SAT

To obtain SAT expression in any of the subcellular compartments (cytosol, mitochondrion or chloroplast), the transgene is introduced into the appropriate vector, which is described in Figure 12.

A kanamycin-resistance gene (NPTII) which encodes neomycin phosphotransferase, and which is used as a selection marker for transforming tobacco, is cloned between the left (LE) and right (RE) edges of the t-DNA. Expression of the NPTII gene is under the control of the promoter and of the terminator of *A. tumefaciens* nopaline synthase. Downstream, the β -glucuronidase gene which has been cloned between the unique *Bam*H1 and the unique *Sac*I sites, is under the control of the cauliflower mosaic virus (CaMV) 35S promoter and nopaline synthase gene polyadenylation signal from the Ti plasmid. The gene encoding the SAT is inserted between the *Bam*H1 and *Sac*I sites of the vector, from which has been deleted the β -glucuronidase gene (Figure 12).

Transgene expression in seeds

A construct similar to that shown in **Figures 11 or 12** is prepared with the aim of obtaining specific expression of the transgene in the seeds. This strategy may be important since seeds make up the main contribution to the animal diet. For this, the constitutive tobacco mosaic promoter is replaced with a promoter which allows specific expression of the transgene during the setting up of the seeds' stocks.

10

Example 10. Transformation of tobacco

Young leaves of tobacco plants (aged from 3 to 4 weeks) whose surface is sterilized with a 10% (V/V) solution of bleach for 10 min then rinsed with sterile water, are cut up with a punch (30 discs per construct). 20 ml of a 48-hour culture of *Agrobacterium tumefaciens* EHA105 (containing the pBI121 vector modified according to the invention) are centrifuged and then resuspended in 4 ml of a 10 mM solution of MgSO_4 . The foliar discs are incubated for a few minutes in the solution of agrobacteria, then transferred to MS medium (Sigma M-5519) supplemented with 0.05 mg/l of α -naphthaleneacetic acid (NAA, Sigma), 2 mg/l of 6-benzylaminopurine (BAP) and 7 mg/l of phytoagar, for 2 to 3 days. The foliar discs are then transferred to an identical medium to which are added 350 mg/l of cefotaxin (bacteriostatic) and 75 mg/l of kanamycin (selection agent). After 2 weeks, discs on which have

developed calli as well as young shoots, are subcultured in identical medium in order to accelerate growth of the shoots. A week later, the green shoots are excised and transferred into the same medium, without hormone, in order to allow the development of roots, this for about 2 weeks, at the end of which the young plants are transferred into earth and cultivated in a hothouse.

10 Example 11. Analysis of results for SAT3 and SAT1' (L78443) (truncated form of the SAT1 U22964) transgenic plants and controls

The impact of the expression of SAT3, SAT1' or OTP-SAT3 in leaves or in seeds of tobacco plants is analysed as regards the content of sulphur compounds; cysteine, methionine (and derivatives such as S-methylmethionine or SMM) and glutathione. The cysteine and glutathione are evidenced by the method of Fahey ([33] Fahey, R.C. and Newton, G.L. Methods Enzymol. (1987) 143, 85-96), after derivatization of the compounds by thiolite (mBBR from Calbiochem) and separation by high performance liquid chromatography (HPLC) [33]. The free methionine and SMM are assayed by the methods for assaying free amino acids after extraction, derivatization with ortho-phthalaldehyde, and separation by HPLC ([34] Brunet, P. et al., J. Chrom. (1988) 455, 173-182). The serine acetyltransferase activity is measured as described in

the methodology for assay of formed O-acetylserine, by the HPLC technique, or by the method of coupling in the presence of an excess of O-acetylserine (thiol) lyase [12], [14]. The SAT transgene activity in transformed plants (i.e. *in vivo*) is revealed by assaying the O-acetylserine, which is produced during activity of the enzyme and is transiently accumulated in the cell.

The O-acetylserine in the plant extracts is assayed following the protocol below.

After crushing tobacco leaves to a fine powder in liquid nitrogen, the extracts are taken up in 0.1 M hydrochloric acid (1 ml/100 mg of powder). After an incubation period of about 10 min, the debris is eliminated by centrifugation for 15 min at 15,000 g. A fraction of the obtained supernatant, containing the free amino acids, is derivatized for 1 min at 25°C in the presence of a solution of ortho-phthalaldehyde (solution containing 54 mg of ortho-phthalaldehyde, 10% methanol, 90% sodium borate, 400 mM, pH 9.5, and 0.2 ml of β -mercaptoethanol). The OPA-amino acid derivatives are separated by reverse phase chromatography on a UPHDO-15M column (0.46 \times 150 mm - Interchim) connected to an HPLC system (Waters). The buffers used to carry out the elution are, buffer A: 85 mM sodium acetate, pH 4.5 supplemented with acetonitrile to 6% final; buffer B: 60% acetonitrile in water. Separation of the derivatives is carried out according to the gradient (1 ml/min): 0 min, 30% B in A; 8 min, 60% B in A;

9 min, 80% B in A; 10 min, 100% B; 12 min, 100% B. At the column exit, the fluorescence emitted by the derivatives is measured at 455 nm after excitation at 340 nm (SFM25 fluorimeter, Kontron).

5 The retention time of *O*-acetylserine under our experimental conditions is 9.5 min. The identity of the peak corresponding to *O*-acetylserine is confirmed by co-elution with a known quantity of the pure product. Moreover, a second control is carried out to
10 confirm the position of *O*-acetylserine in the various analyses. The samples, before incubation with OPA, are treated with NaOH at a final concentration of 0.2 M. Under these conditions, the acetate group in the OH position on serine is transferred to the amine group,
15 thus allowing the formation of *N*-acetylserine. This latter compound is no longer detected under our experimental conditions and thus leads to the disappearance of the peak which initially corresponded to *O*-acetylserine.

20 Plants transformed with an SAT transgene were preselected with kanamycin, and run to seed. Control plants (PBI, three independent lines which contain the transforming vector and a GUS cassette) are treated in an identical way. Analyses of the plants comprise: 1;
25 demonstration of insertion of the transgene into the genome by PCR, using the 5' primer and the 3' primer which correspond to the SAT which is used for the transformation; 2, demonstration of the messenger by

analysis of messengers using probes which correspond to the SAT transgenes used for transforming the plants according to known techniques; 3, demonstration of enzyme activity associated with SAT protein according to methods described in the literature [14], and demonstration of transgene localization; 4, assay of the product of the SAT reaction, i.e. *O*-acetylserine (OAS), in transformed plants; 5, assay of cysteine and its direct derivatives, of glutathione and of methionine (and its methylated derivatives); 6, analysis of total amino acid composition of the plants and seeds which are associated with each of the transgenes obtained (free amino acids and amino acids linked to proteins), according to traditional techniques; 7, analysis of the impact of overexpressing SAT activity in plant cells, on the amount of enzyme activity which is associated with the sequence of assimilation of sulphur (sulphate transporters, ATP-sulphurylase, APS reductase, sulphite reductase and in particular *O*-acetylserine (thiol) lyase, the enzyme which is directly associated with SAT activity in cysteine synthesis [14]. Moreover, the enzymes associated with the synthetic pathway of methionine and the synthetic pathway of glutathione, are analysed in order to understand the impact of the cysteine content on the metabolism associated with glutathione synthesis and methionine synthesis.

Expression of the *Arabidopsis thaliana* serine acetyltransferase gene in tobacco leads to an increase in the level of cysteine, the level of glutathione and the level of methionine in tissues of transformed
5 plants, compared to control plants. In general, this increase in the amount of free sulphur compounds is associated with transgene expression in the plant cell (**Figure 13**). Measurement is carried out on leaves from
3 different plants for each homozygous line. The SAT
10 activity is measured as its capacity to promote cysteine synthesis, according to the protocol described above [14].

Expression of the transgene under the control of the constitutive CaMV promoter, causes the SAT
15 capacity (maximum potential enzyme activity measured *in vitro*) to increase by a factor of 2 to 8, compared to the level measured in control plants (plants transformed with an empty vector). To determine the real activity of the SAT transgene, the amount of
20 O-acetylserine (free OAS) was measured. Thus, it was possible to multiply the level of OAS in plant cells (average level of 4 nmol/g of fresh material for control plants, 6 independent measurements) by a factor of 2 to 10, in transformed plants (2 independent
25 measurements). Thus, for most SAT transgenes, associated with the clear increase in the capacity of SAT enzyme activity, is an increase in free intracellular OAS which results from the transgene

activity *in vivo*, and an increase in the amount of free cysteine, compared to control plants (**Figure 14**). The cysteine content in the control plants (PBI) and in the T2 tobacco plants transformed with an SAT (SAT1' and SAT3 lines), is determined as monobromobimane derivatives, by HPLC, for 3 plants per line [33]. The cysteine content of the transgenic lines is increased 2- to 10-fold in comparison with control plants (PBI).

The amount of free cysteine in most transgenic plants which express an SAT is significantly higher, 2 to 10-fold, than the natural level which is measured in control plants PBI (of a value of 5 nmol/g of fresh material, average calculated from three independent lines, each containing 5 plants). This impact of SAT expression is observed as early as the T1 generation. On the other hand, no correlation could be seen between amount of cysteine (and moreover of free OAS) and the SAT activity from transgenes which are measured *in vitro*. On the other hand, a significant positive correlation could be measured between amount of cellular OAS and cysteine level in the cell (**Figure 15**). *In vivo*, a 3- to 10-fold increase, compared to control plants, in the level of free O-acetylserine, which is linked to transgene activity, results in a 3- to 8-fold increase in the level of cysteine in the plants. Analysis was carried out on fully developed leaves (about 2 months) of plants homozygous for the transgene. The control plants are

plants transformed with empty constructs (PBI). An increase in the amount of free cellular OAS which is linked to SAT transgene activity in transformed plants, correlates positively with increase in the amount of cysteine. Thus, an average 6-fold increase in the level of free OAS is associated with a 6-fold increase in the level of cysteine. The slope associated with the distribution of the points is 1.06 ± 0.09 (coefficient of regression 0.67). It indicates that for each molecule of OAS accumulated, one mole of cysteine is synthesized. The value of this slope and the absence of a plateau observed under our experimental conditions, indicate the sulphide formation (assimilation of sulphate and reduction to sulphide) is not a limiting pathway and that SAT activity seems to be the limiting factor in the cell for cysteine formation (**Figure 1**).

The subcellular localization of the SAT1' (truncated form of SAT1) transgene and the SAT3 transgene in transformed tobacco plants was made clear by preparation of the chloroplast fraction of transformed plants which present the highest enzyme activity, compared with PBI plants (controls). The activity associated with the chloroplast compartment is compared with that measured in the total extract (**Figure 16**). The values for serine acetyltransferase activity correspond to 3 lines for the PBI plants (5 plants per line), to 5 lines for SAT1' and SAT3, each

being represented by 5 plants. The columns in grey correspond to the activities measured in the total extract from each of the lines, and the columns in black represent the average of the activities measured
 5 in each of the chloroplast preparations.

These results establish definitively that SAT3 is an isoform of the serine acetyltransferase located in the cytosol of plant cells, and that the truncated form of SAT1 (absence of transit peptide) is
 10 also located in the cytosolic compartment. With regard to SAT3, these results confirm our interpretations which are derived from analysis of the protein sequence [12].

A direct consequence of increasing the level
 15 of cellular cysteine is increased synthesis of glutathione and methionine (see **Figure 1**). Cysteine is destined for multiple usage and besides its incorporation into proteins, and its participation in the synthesis of multiple compounds, such as vitamins
 20 (biotin, thiamine, etc. and other sulphur derivatives in the cell), cysteine also participates in the synthesis of glutathione (tripeptide which is associated with numerous plant defence mechanisms and which is considered to be a reservoir for cysteine) and
 25 of methionine. Specifically in plants which are transformed with the SAT transgene, the level of glutathione correlates directly with that of cysteine, and is reflected by an increase of 2 to 7 times the

natural level which is measured in control plants (PBI) (Figure 17). The correlation coefficient which is calculated for the distribution of the points is 0.92. A 4-fold increase in cysteine content in transgenic tobacco plants which overexpress SAT results in a 3- to 4-fold increase in the level of glutathione. Analysis was carried out using fully developed leaves (about 2 months) from plants homozygous for the transgene. The control plants are plants which are transformed with empty constructs.

This result indicates that cysteine is the limiting factor in glutathione synthesis in the plant cell. Thus, indirectly, the consequence of any modification of the level of serine acetyltransferase in the cell, will be to increase the amount of intracellular glutathione, by increasing the level of cysteine. This result implies that the transgenic plants obtained have acquired properties of stress resistance compared to the control plants (PBI). This aspect was observed recently ([34] Blaszczyk A. et al., 1999, The Plant Journal 20, 237-243). Moreover, the amount of cysteine and of glutathione which is considered to be a reservoir, brings about increased availability at the time of synthesis of polypeptides rich in cysteine (for example for resistance to phytopathogenic attack), and rich in cysteine and in methionine (for animal foods).

An increase in cysteine in the plant cell also brings about an increase in the relative amount of methionine (**Figure 18**). On the other hand, unlike the results observed for glutathione, the curve has a plateau, which seems to indicate the existence of another control site which would limit methionine synthesis. Moreover, homocysteine, which is derived from the trans-sulphuration pathway, and is the sulphur precursor in methionine synthesis, does not seem to accumulate. This observation thus indicates that the folate pool in the plant cell, which is essential for methylation and for methionine formation, is not a limiting factor. This limitation would thus be situated downstream of cysteine and upstream of homocysteine. It concerns the synthesis of the carbon precursor for the aspartate-derived methionine synthesis (*O*-phosphohomoserine and/or cystathionine). The level of aspartokinase (the first enzyme of the aspartate pathway for the synthesis of lysine, threonine and methionine) is controlled by several effectors, such as threonine and *S*-adenosylmethionine (SAM) which comes from methionine synthesis [3]. Cystathionine γ -synthase (see **Figure 1**) is directly regulated at the transcriptional level [3] and, more exactly, methionine or one of its derivatives controls the stability of its messenger [4]. The maximum plateau which is obtained under our experimental conditions is of the order of 39 \pm 7 nmol of methionine/g of fresh material, which

corresponds to a multiplication of the average natural level which is of the order of 6. +/- 2 nmol per g of fresh material (PBI control). The maximum value which is obtained for methionine requires an increase in the amount of cysteine in the cell of 4 to 5 times its natural level. The regression coefficient is 0.50.

Moreover, an increase in the methionine in the cells causes the level of *S*-methylmethionine (SMM) to multiply from 2- to 10-fold, according to the plant. SMM is derived directly from the methylation of methionine in the presence of *S*-adenosylmethionine. This compound is important to the cell, and is a form of transport of methyl groups (of methionine) in the plant. In the presence of one molecule of homocysteine (the sulphur precursor in methionine synthesis, and which is derived from cysteine), SMM allows the synthesis of two molecules of methionine ([3], [35], Bourgis et al., 1999, Plant Cell 11, 1485-1497). It may thus have a primordial role at the time of storage protein synthesis in the seed. Moreover, SMM is the direct precursor for the synthesis of compounds such as 3-dimethylsulphoniopropionate which is involved in the resistance of plants to salt stress ([36] Hanson A.D. et al., 1994, Plant Physiol. 105, 103-110). Such an approach has many consequences, in particular for increasing the potentialities of plants on grounds rich in salt.

Evidence for a regulatory role in the sulphate assimilation pathway *in vivo*.

Serine acetyltransferase is taken to be a limiting factor for the assimilation of sulphur and for the synthesis of cysteine. Its role in bacteria is important since the reaction product, (O-acetylserine, OAS) or its derivative (N-acetylserine), is the effector which modulates the expression of the genes of the sequence of assimilation of sulphur, such as:

- 1, sulphate transport, 2, ATP sulphurylase, 3, APS kinase, and 4, PAPS reductase ([37] Kredich N.M., 1987, in *Escherichia coli* and *Salmonella typhimurium*: cellular and molecular biology, pp. 419-428). In plants, a role has been shown for OAS in modulating the expression of several genes, which concerns sulphate transporters, ([38] Smith F.W. et al., 1997, *The Plant Journal* 12, 875-884; [39] Hawkesford M.J. et al. 1995, *Z. Pflanzenernährh. Bodenk.* 158, 55-57; [40] Clarkson D.T. et al. 1999, *Plant Physiol. Biochem.* 37, 283-290), ATP sulphurylase [39-40] and APS reductase ([41] Neuenschwander U. et al. 1991, *Plant Physiol.*, 97, 253-258). The role of serine acetyltransferase activity in gene modulation has been proposed based on the kinetics of the cysteine synthase complex (bienzyme complex composed of serine acetyltransferase and of O-acetylserine (thiol) lyase) ([41] Droux et al. in *Sulphur and Nutrition in Plants*, in press), and has led to the description of a model to describe the mechanism

of gene regulation. The role of OAS is also determinant in the regulation of gene expression during seed formation ([42] Kim H. et al., 1999, *Planta* 209, 282-289).

- 5 In transgenic plants which overexpress an SAT in the cytosol, a transient increase in OAS was shown (increase of 2 to 10 times its natural level, see **Figure 15**). In parallel, in most transgenic plants, an increase in OASTL activity was measured (**Figure 19**).
- 10 This increase of 2 to 5 times compared to the activity which is measured in PBI controls, concerns only the chloroplast-associated activity. Moreover, in a Western Blot, the signal which is observed is stronger in most transgenic lines (**Figure 20**), indicating that the
- 15 increase in activity corresponds to an induction of *de novo* synthesis of OASTL. This original result corresponds to the first demonstration of the role of OAS (*in planta*) in the modulation of genes of the sulphate assimilation pathway, in particular for
- 20 chloroplast OASTL.

- Referring to **Figure 20**, an equivalent amount of protein (0.150 mg) undergoes SDS-PAGE (12%), and after separation, the proteins are transferred onto a nitrocellulose membrane. The presence of OASTL is
- 25 revealed by incubation with antibodies which have been raised against chloroplast OASTL from spinach leaves [7].

Overexpression of SAT in plant cells thus causes the capacity to synthesize cysteine in the chloroplast to increase. It can, therefore, be assumed that the expression of genes encoding enzymes of the sulphate assimilation and reduction pathway (sulphate transporter, ATP sulphurylase, APS reductase, sulphite reductase) is also modulated like OASTL (and references [38-41]).

The increase in the intracellular content of OAS (which is derived from SAT activity) signals a state of artificial sulphur stress (absence of sufficient reduced sulphur) in the cell (in transformed plants), which leads to induction of the enzymes of the sulphate assimilation pathway.

15

Impact of increasing cysteine in a cell on the general content of amino acids. This increase in sulphur compounds is accompanied by an increase in the content of essential amino acids, such as threonine, isoleucine and lysine (their amount is doubled, on average). On the other hand, the level of glutamate is halved, as is that of aspartate. This latter observation is directly linked to the increase in the amount of THR, LYS and ILE. All the increases in amino acids correlate with an increase in serine acetyltransferase (SAT3 or SAT1') activity in the cytosol. Moreover, an increase in these sulphur compounds leads to an improvement in the nutritional ratio N/S of the plant (on the basis of

25

free amino acids). It is reflected by a drop in this relative ratio, due to the enrichment in total sulphur compounds (cysteine, methionine, SMM and glutathione). This factor is important since it conditions the

5 polypeptide content of the seeds, and leads to enrichment (or impoverishment if the N/S ratio is too high) of storage proteins which are rich in sulphur-containing amino acids, to the detriment of polypeptides which are lacking in these compounds.

10

Example 12. Analysis of OTP-SAT3 (OTP-SAT1') transgenic plants

Analysis of transformants at the T0 stage of transgenic plants which express a cysteine-insensitive

15 SAT (here for example, SAT3 or SAT1'; truncated form of SAT1 U22964), in leaves or in seeds (under the control of a seed-specific promoter), reveals an increase in free cysteine content, but also in glutathione content (2.6 times the natural level), and in methionine

20 content. Plants which express these same isoforms in the cytosol under the control of a seed-specific promoter show a level of sulphur compounds which is higher than in control plants.

Example 13. Analysis of results for SAT1 (cDNA U22964 or SAT1jw, transit peptide form) transgenic plants and control plants.

The impact of expression of serine
 5 acetyltransferase in mitochondria was analysed by
 transforming plants with the construct (**Figure 12**)
 which contains the entire SAT1 sequence. Analysis of
 plants at the T0 stage makes it possible to show an
 increase in free cysteine in the cell (**Figure 21**).
 10 Analysis is carried out on leaves which are formed
 before appearance of the floral scape. The fourteen
 lines show a 2- to 6-fold multiplication in cysteine
 level, compared with the control plant (PBI).

The increase in cysteine is accompanied by a
 15 general effect on the amount of sulphur compounds, with
 a 4-fold multiplication in the amount of glutathione
 in the cell (**Figure 22**). Unlike the case of SAT
 expression in the cytosolic compartment, the general
 appearance of the distribution of values in the
 20 different lines, shows a plateau which would indicate
 limitation in glutathione synthesis. This limitation
 may concern the level of glutamate and/or glycine or
 may concern glutathione control of its own synthesis
 (retroinhibition of one of the enzymes which
 25 participate in glutathione synthesis, enzyme E6 and/or
 enzyme E7 see **Figure 1**).

Claims

1. Method for increasing the production of cysteine, glutathione and methionine, and of sulphur derivatives thereof, by plant cells and plants, the
5 said method consisting in overexpressing an SAT in plant cells and plants containing the said plant cells.

2. Method according to claim 1, characterized in that the SAT which is overexpressed in plant cells is a cysteine-sensitive SAT.

10 3. Method according to claim 2, characterized in that the SAT is a plant SAT or a native SAT of bacterial origin.

4. Method according to claim 1, characterized in that the SAT which is overexpressed in
15 plant cells is a cysteine-insensitive SAT.

5. Method according to claim 4, characterized in that the SAT is a plant SAT or an SAT of bacterial origin, or a mutated plant SAT, rendered cysteine-insensitive by mutagenesis.

20 6. Method according to one of claims 1 to 5, characterized in that the SAT is overexpressed in the cytoplasm of plant cells.

7. Method according to claim 6, characterized in that the SAT is an SAT of bacterial
25 origin.

8. Method according to claim 6, characterized in that the SAT is a plant cytoplasmic SAT, in particular from *Arabidopsis thaliana*.

9. Method according to claim 8,
characterized in that the SAT is SAT3 which is
represented by SEQ ID NO 1.

10. Method according to claim 6,
5 characterized in that the SAT is a non-cytoplasmic
plant SAT from which has been removed its signal(s) for
addressing to cellular compartments other than the
cytoplasm.

11. Method according to claim 10,
10 characterized in that the SAT is SAT1' which is
represented by SEQ ID NO 2.

12. Method according to one of claims 1 to
5, characterized in that the SAT is overexpressed in
mitochondria.

13. Method according to claim 12,
15 characterized in that the SAT is overexpressed in the
cytoplasm in the form of a signal peptide/SAT fusion
protein, the mature functional SAT being released
inside mitochondria.

14. Method according to claim 13,
20 characterized in that the mitochondrial addressing
signal peptide consists of at least one signal peptide
from a natural plant protein which is located in
mitochondria, such as for example, the SAT1 signal
25 peptide which is represented by amino acids 1 to 63 in
SEQ ID NO 3.

15. Method according to claim 13,
characterized in that the SAT is a mitochondrial SAT of
plant origin, in particular from *Arabidopsis thaliana*.

16. Method according to claim 15,
5 characterized in that the SAT is SAT1 which is
represented by SEQ ID NO 3.

17. Method according to claim 6,
characterized in that the SAT is overexpressed in
chloroplasts of plant cells.

10 18. Method according to claim 17,
characterized in that the SAT is overexpressed in
chloroplasts by integration, into chloroplast DNA of
plant cells, of a chimeric gene comprising a DNA
sequence encoding the said SAT, under the control of 5'
15 and of 3' regulatory elements which are functional in
chloroplasts.

19. Method according to claim 17,
characterized in that the SAT is overexpressed in the
cytoplasm in the form of a transit peptide/SAT fusion
20 protein, the mature functional SAT being released
inside chloroplasts.

20. Method according to claim 19,
characterized in that the SAT is homologous with the
transit peptide.

25 21. Method according to claim 20,
characterized in that the SAT is a chloroplast SAT of
plant origin, in particular from *Arabidopsis thaliana*.

22. Method according to claim 21,
characterized in that the SAT is SAT2 or SAT4 which are
represented by SEQ ID NO 5 or NO 6, respectively.

23. Method according to claim 19,
5 characterized in that the SAT is heterologous with the
transit peptide.

24. Method according to claim 13,
characterized in that the SAT is a cytoplasmic SAT of
plant origin or an SAT of bacterial origin, as defined
10 in one of claims 3 to 5 or 9 to 11.

25. Method according to either of claims 23
and 24, characterized in that the transit peptide is a
transit peptide from another protein which is located
in plastids.

15 26. Method according to claim 25,
characterized in that the transit peptide consists of a
plant EPSPS transit peptide or a plant RuBisCO ssu
transit peptide.

27. Method according to either of claims 25
20 and 26, characterized in that the transit peptide
comprises a transit peptide from a plant protein which
is located in plastids, and, between the C-terminal
portion of the transit peptide and the N-terminal
portion of the SAT, a portion of sequence from the
25 mature N-terminal region of a protein which is located
in plastids.

28. Method according to claim 27,
characterized in that the portion of sequence comprises

generally less than 40 amino acids from the N-terminal portion of the mature protein, preferably less than 30 amino acids, more preferably between 15 and 25 amino acids.

5 29. Method according to either of claims 27 and 28, characterized in that the transit peptide comprises, between the C-terminal portion of the N-terminal portion of the mature protein and the N-terminal portion of the SAT, a second transit peptide
10 from a plant protein which is located in plastids.

 30. Method according to claim 29, characterized in that the transit peptide is an optimized transit peptide (OTP) made by fusing a first
15 mature N-terminal region of a protein located in plastids, which is fused with a second transit peptide.

 31. Transit peptide/SAT fusion protein, characterized in that the SAT is heterologous with the transit peptide.

20 32. Fusion protein according to claim 31, as defined in claims 24 to 30.

 33. Nucleic acid sequence encoding a transit peptide/SAT fusion protein according to either of claims 31 and 32.

25 34. Chimeric gene comprising a coding sequence as well as heterologous 5' and 3' regulatory sequences, which are able to function in a host organism, characterized in that the coding sequence

comprises at least one nucleic acid sequence which encodes an SAT.

35. Chimeric gene according to claim 34, characterized in that the host organism is chosen from
5 bacteria, for example *E. coli*, yeasts, in particular of the genera *Saccharomyces*, *Kluyveromyces* or *Pichia*, fungi, in particular *Aspergillus*, baculoviruses, or plant cells and plants.

36. Chimeric gene according to claim 35,
10 characterized in that the host organism is a plant cell or a plant which contains it .

37. Chimeric gene according to claim 36, characterized in that the 5' regulatory element comprises regulatory sequences which are promoters in
15 plant cells and plants, and are chosen from promoters which are expressed in plant leaves, constitutive promoters, or light-dependent promoters of bacterial, viral or plant origin.

38. Chimeric gene according to claim 36,
20 characterized in that the 5' regulatory element comprises regulatory sequences which are promoters in plant cells and plants, and are chosen from seed-specific promoters.

39. Chimeric gene according to claim 38,
25 characterized in that the promoter is chosen from the promoters for napin, phaseolin, glutenin, zein, helianthinin, albumin and oleosin.

40. Chimeric gene according to one of claims 34 to 39, characterized in that the nucleic acid sequence which encodes an SAT encodes an SAT as defined in claims 2 to 30.

5 41. Chimeric gene according to one of claims 34 to 39, characterized in that the nucleic acid sequence which encodes an SAT is the nucleic acid sequence according to claim 33.

10 42. Cloning and/or expression vector for transforming a host organism, characterized in that it contains at least one chimeric gene as defined according to one of claims 34 to 41.

15 43. Method of transforming host organisms, characterized in that at least one nucleic acid sequence according to claim 33, or a chimeric gene according to one of claims 34 to 41, is integrated into the genome of the said host organism.

44. Method according to claim 43, by means of the vector according to claim 42.

20 45. Method according to either of claims 43 and 44, characterized in that the host organism is chosen from bacteria, for example *E. coli*, yeasts, in particular of the genera *Saccharomyces*, *Kluyveromyces* or *Pichia*, fungi, in particular *Aspergillus*,
25 baculoviruses, or plant cells and plants.

46. Method according to claim 45, characterized in that the host organism is a plant cell or a plant which contains it.

and/or crossing of regenerated plants, according to claim 53.

55. Genetically modified plant according to one of claims 52 to 54, characterized in that it is a
5 monocotyledonous plant, in particular chosen from cereals, sugar cane, rice and maize, or a dicotyledonous plant, in particular chosen from tobacco, soybean, rape, cotton, beet and clover.

56. Genetically modified plant according to
10 one of claims 52 to 55, characterized in that it comprises other genes of interest.

57. Genetically modified plant according to claim 56, characterized in that it comprises at least one other gene which modifies the content and quality
15 of the proteins of the said plant, in particular in the leaves and/or seeds.

58. Genetically modified plant according to either of claims 56 and 57, characterized in that the gene encodes a protein enriched in sulphur-containing
20 amino acids.

59. Seeds of genetically modified plants according to one of claims 52 to 58.

**Method for increasing the content of sulphur compounds
and in particular of cysteine, methionine and
glutathione in plants, and plants obtained**

RHONE-POULENC AGRO

Descriptive abstract

The present invention relates to a method for increasing the production of cysteine, methionine, glutathione and derivatives thereof, by plant cells and plants, the said method consisting in overexpressing an SAT in plant cells, and to plants which contain the said plant cells.

1/12




Figure 1 : Séquence illustrant la voie de synthèse de la cystéine et des dérivés soufrés (glutathion et méthionine).




Figure 2 : Effet de la cystéine sur les activités sérine acétyltransférase de pois (*Pisum sativum*).




Figure 3 : Modèle de l'inhibition de la sérine acétyltransférase chloroplastique.

[illegible][illegible][illegible]

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | | M | P | P | A | G | E | T | A | T | Q | S | P | S | K | 14 |
| | | ATG | CCA | CCG | GCC | GGA | GAA | CTC | CGA | CAT | CAA | TCT | CCA | TCA | AAG | 42 |
| E | K | L | S | S | V | T | Q | S | D | T | A | F | A | A | S | 30 |
| GAG | AAA | CTA | TCT | TCC | GTT | ACC | CAA | TCC | GAT | GAA | GCA | GAA | GCA | GCG | TCA | 90 |
| A | A | T | S | A | A | A | A | D | A | E | A | A | C | T | W | 46 |
| GCA | GCG | ATA | TCT | GCG | GCA | GCT | GCA | GAT | GCG | GAA | GCT | GCC | GGA | TTA | TGG | 138 |
| T | Q | T | K | A | E | A | R | K | D | A | T | A | T | P | A | 62 |
| ACA | CAG | ATC | AAG | GCG | GAA | GCT | CGC | CGT | GAT | GCT | GAG | GCG | GAG | CCA | GCT | 186 |
| L | A | S | Y | L | I | S | T | L | S | H | S | S | L | E | | 78 |
| TTA | GCT | AGC | TAT | CTA | TAT | TCG | ACG | ATT | CTT | TCT | CAT | TCG | TCT | CTT | GAA | 234 |
| R | S | T | S | F | T | L | G | V | L | C | S | S | T | T | | 34 |
| CGA | TCT | ATC | TCG | TTT | CAT | CTA | GGA | AAC | AAG | CTT | TGT | TCC | TCA | ACG | CTT | 282 |
| L | S | T | L | L | V | D | L | F | L | N | T | F | S | S | D | 110 |
| TTA | TCC | ACA | CTT | TTA | TAC | GAT | CTG | TTC | TTA | AAC | ACT | TTT | TCC | TCC | GAT | 330 |
| P | S | L | R | N | A | T | V | A | D | R | A | A | R | V | | 126 |
| CCT | TCT | CTT | CGT | AAC | GCC | ACC | GTC | GCA | GAT | CTA | CGC | GCT | GCT | CGT | GTT | 378 |
| R | D | P | A | C | T | S | V | S | T | C | T | C | N | Y | K | 142 |
| CGT | GAT | CCT | GCT | TGT | ATC | TCG | TTT | TCT | CAT | TGT | CTC | CTC | AAT | TAC | AAA | 426 |
| G | F | L | A | T | Q | A | H | P | V | T | C | H | K | T | W | 158 |
| GGC | TTC | TTA | GCT | ATT | CAG | GCG | CAT | CGT | GTA | TCA | CAC | AAG | CTA | TGG | ACA | 474 |
| Q | S | R | K | P | L | A | L | R | L | H | S | R | T | S | D | 174 |
| CAA | TCA | CGG | AAG | CCA | TTA | GCA | TTA | GCT | CTA | CAC | TCA | AGA | ATC | TCC | GAT | 522 |
| V | F | A | V | D | T | H | P | A | L | K | T | G | K | C | T | 120 |
| GTA | TTC | GCT | GTT | GAT | ATC | CAT | CCA | GCA | GCG | AAG | ATC | GGA | AAA | GGG | ATA | 570 |
| L | L | D | H | A | T | G | T | T | V | C | E | T | A | V | T | 206 |
| CTT | CTA | GAC | CAC | GCA | ACC | GGA | GTT | GTA | GTC | GGA | GAA | ACA | GCG | GTG | ATT | 618 |
| B | N | N | V | S | T | L | H | R | T | T | L | G | G | T | C | 222 |
| GGG | AAC | AAT | GTT | TCA | ATC | CTT | CAC | CAT | GTG | ACA | CTA | GGT | GGA | ACA | GGT | 666 |
| N | A | C | G | D | R | H | P | K | T | G | D | G | C | T | T | 238 |
| AAA | GCT | TGT | GGA | GAT | AGA | CAT | CCG | AAG | ATC | GGT | GAC | GGT | TGT | TTG | ATT | 714 |
| G | A | G | A | T | A | V | E | N | V | K | T | G | A | G | A | 254 |
| GGA | GCT | GGA | GCG | ACT | ATT | CTT | GGA | AAT | GTG | AAG | ATT | GGT | GCA | GGT | GCT | 762 |
| K | V | G | A | G | S | V | T | T | D | V | D | C | P | G | | 170 |
| AAA | GTA | GGA | GCT | GGT | TCT | GTT | GTG | CTG | ATT | GAC | GTG | CCT | TGT | CGA | GGT | 810 |
| T | A | V | G | N | P | A | R | T | T | C | C | K | E | K | P | 236 |
| ACT | GCG | GTT | GGG | AAT | CCG | GCG | AGA | CTT | GTC | GGA | GGG | AAA | GAG | AAG | CCA | 858 |
| T | T | H | D | E | E | C | P | G | E | S | M | D | H | T | C | 302 |
| ACG | ATT | CAT | GAT | GAG | GAA | TGT | CCT | GGA | GAA | TCG | ATG | GAT | CAT | ACT | TCA | 906 |
| C | T | S | E | N | G | T | V | T | T | T | T | T | T | T | T | 312 |
| TTC | ATC | TCG | GAA | TGG | TCA | GAT | TAC | ATC | ATA | TAA | | | | | | 939 |

Figure 5: Séquence nucléotidique et peptidique du gène de l'isoforme SAT3' (U30298) d'*A. thaliana*

4/12

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ATG | GCT | GCG | TGC | ATC | GAC | ACC | TGC | CGC | ACT | GGT | AAA | CCC | CAG | ATT | 15 |
| S | P | R | D | S | S | A | T | G | C | G | A | P | A | T | 45 |
| TCT | CCT | CGC | GAT | TCT | TCT | AAA | CAC | CAC | GAC | GAT | GAA | TCT | GGC | TTT | 30 |
| L | T | M | N | Y | F | A | L | P | D | R | S | S | F | T | 90 |
| CGT | TAC | ATG | AAC | TAC | TTC | CGT | TAT | CCT | GAT | CGA | TCT | TCC | TTC | AAT | 45 |
| L | T | C | T | A | A | T | A | T | A | C | T | T | C | A | 135 |
| GGA | ACC | CAG | ACC | AAA | ACC | CTC | CAT | ACT | CGT | CCT | TTG | CTT | GAA | GAT | 60 |
| L | D | R | D | A | E | V | D | D | V | T | A | T | I | E | 180 |
| CTC | GAT | CGC | GAC | GCT | GAA | GTC | GAT | GAT | GTT | TGG | GCC | AAA | ATC | CGA | 75 |
| E | E | A | K | S | D | I | A | N | E | E | I | A | T | C | 225 |
| GAA | GAG | GCT | AAA | TCT | GAT | ATC | GCC | AAA | GAA | CCT | ATT | GTT | TCC | GCT | 90 |
| V | H | A | S | L | / | S | Q | R | S | L | E | - | - | - | 270 |
| TAT | TAT | CAC | GCT | TCG | ATT | GTT | TCT | CAG | CGT | TCG | TTG | GAA | GCT | GCG | 105 |
| L | A | N | T | L | S | T | R | L | S | N | L | N | L | P | 315 |
| TTG | GCG | AAT | ACT | TTA | TCT | GTT | AAA | CTC | AGC | AAT | TTG | AAT | CTT | CCA | 120 |
| T | N | T | L | F | D | L | F | C | C | T | L | - | - | - | 360 |
| AGC | AAC | ACG | CTT | TTC | GAT | TTG | TTC | TCT | GGT | GTT | CTT | CAA | GGA | AAC | 135 |
| E | D | I | V | E | S | T | K | L | D | L | I | A | V | E | 405 |
| CCA | GAT | ATT | GTT | GAA | TCT | GTC | AAG | CTA | GAT | CTT | TTA | GCT | GTT | AAG | 150 |
| T | R | D | P | A | C | L | S | L | V | A | D | F | L | - | 450 |
| GAG | AGA | GAT | CCT | GCT | TGT | ATA | AGC | TAC | GTT | CAT | TGT | TTC | CTT | CAC | 165 |
| H | K | C | F | L | A | T | Q | L | E | P | L | L | H | E | 495 |
| TTT | AAA | GGC | TTC | CTC | GCT | TGT | CAA | GCG | CAT | CGT | ATT | GCT | CAT | GAG | 180 |
| L | V | L | C | D | S | N | L | L | L | L | L | L | L | L | 540 |
| CTT | TGG | ACT | CAG | GAC | AGA | AAA | ATC | CTA | GCT | TTG | TTG | ATC | CAG | AAC | 195 |
| S | A | A | - | - | - | - | - | - | - | - | - | - | - | - | 585 |
| AGA | GTC | TCT | GAA | GCC | TTC | GCT | GTT | GAT | TTC | CAC | CCT | GGA | GCT | AAA | 210 |
| E | - | G | - | - | - | - | - | - | - | - | - | - | - | - | 630 |
| ATC | GGT | ACC | GGG | ATT | TTG | CTA | GAC | CAT | GCT | ACG | GCT | ATT | GTG | ATC | 225 |
| L | - | A | / | G | - | - | - | - | - | - | - | - | - | - | 675 |
| GGT | GAG | ACG | GCG | GTT | GTG | GGG | AAC | AAT | GTT | TCG | ATT | CTC | CAT | AAC | 240 |
| T | T | G | G | G | G | A | G | G | G | G | G | G | G | G | 720 |
| GTT | ACG | CTT | GGA | GGA | ACG | GGG | AAA | CAG | TGT | GGA | GAT | AGG | CAC | CCG | 255 |
| L | G | C | G | / | - | - | - | - | - | - | - | - | - | - | 765 |
| AAG | ATT | GGC | GAT | GGG | GTT | TTG | ATT | GGA | GCT | GGG | ACT | TGT | ATT | TTG | 170 |
| P | N | L | T | L | G | E | G | A | K | L | G | A | S | C | 810 |
| GGG | AAT | ATC | ACG | ATT | GGT | GAA | GGA | GCT | AAG | ATT | GGT | GCG | GGG | TCG | 285 |
| T | V | L | K | D | V | P | E | R | T | F | L | T | - | N | 855 |
| GTG | GTG | TTG | AAA | GAC | GTG | CCG | CCG | CGT | ACG | ACG | GCT | GTT | GGA | AAT | 300 |
| E | L | R | L | L | C | K | C | A | E | K | T | I | I | D | 900 |
| CCG | GCG | AGG | TTG | CTT | GGT | GGT | AAA | GAT | AAT | CCG | AAA | ACG | CAT | GAC | 315 |
| A | - | P | G | L | T | - | D | D | T | S | P | T | C | - | 945 |
| AAG | ATT | CCT | GGT | TTG | ACT | ATG | GAC | CAG | ACG | TCG | CAT | ATA | TCC | GAG | 330 |
| T | S | D | Z | - | - | - | - | - | - | - | - | - | - | - | 990 |
| TGG | TCG | GAT | TAT | GTA | ATT | TGA | - | - | - | - | - | - | - | - | 336 |

1011

Figure 6: Séquence nucléotidique et peptidique d'un gène de l'isoforme SAT 1' (L78443) d'*A. thaliana*.

5/12

| | | | | | | | | | | | | | | | 30 | 10 |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|----|----|
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |

6/12

| M | V | D | L | S | S | F | S | L | L | F | A | F | S | V | S | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| ATG | GTG | GAT | CTA | TCT | TCC | TTT | AGC | CTC | CTT | TTT | GCT | TTC | TCC | GTC | TCT | 48 |
| L | S | F | V | Q | S | K | R | V | C | D | S | S | L | S | | |
| CTC | TCT | TTT | GTC | CAA | TCA | AAA | AGA | GTT | TGT | GAT | TCT | TCT | TTA | TCG | TCT | 96 |
| P | W | R | D | V | N | B | D | Y | L | T | F | E | D | P | | |
| CCT | TGG | AGA | GAT | ATG | AAT | GGC | GAT | GAG | CTT | CCT | TTC | GAG | AGT | GGT | TTC | 144 |
| H | Y | Y | L | A | P | T | H | K | S | E | F | D | S | I | | |
| GAG | GTT | TAC | GCT | AAG | GGA | ACT | CAT | AAG | TCA | GAG | TTT | GAC | TCG | AAT | TTG | 192 |
| L | D | P | R | C | D | L | I | W | D | R | L | R | F | C | | |
| CTT | GAT | CCT | CGT | TCT | GAT | CCT | ATT | TGG | GAT | GCT | ATA | AGA | GAA | GAA | GCT | 240 |
| K | L | E | A | L | A | L | C | L | S | S | A | L | L | A | | |
| AAA | CTT | GAG | GCA | GAG | AAA | GAG | CCT | ATT | TTG | AGT | AGC | TTC | TTG | TAT | GCT | 288 |
| G | L | L | A | L | L | D | L | C | Q | A | L | G | F | C | | |
| GGT | ATC | TTA | GCA | CAT | GAT | TGT | TTA | GAG | CAA | GCT | TTA | GGG | TTT | GTT | CTA | 336 |
| D | N | R | L | D | L | E | D | L | L | A | D | L | L | D | | |
| GCC | AAC | CGT | CTC | CAA | AAC | CCA | ACC | TTG | TTG | GCA | ACA | CAA | CTC | TTG | GAT | 384 |
| I | P | Y | G | V | M | M | H | D | K | G | I | L | S | C | I | |
| ATA | TTT | TAT | GGT | GTT | ATG | ATG | CAT | GAC | AAA | GGT | ATT | CAG | AGT | TCG | ATT | 432 |
| R | H | D | L | Q | A | F | K | D | P | D | P | A | C | L | C | |
| CGC | CAT | GAT | CTC | CAG | GCA | TTT | AAA | GAT | CGT | GAT | CCT | GCT | TGT | CTG | TCG | 480 |
| Y | S | S | A | L | L | H | L | K | G | Y | H | R | L | D | L | |
| TAT | AGT | TCT | GCT | ATT | TTA | CAT | CTG | AAG | GGT | TAT | CAT | GCG | TTA | CAA | GCA | 528 |
| T | P | T | A | E | N | L | W | N | E | C | P | N | L | L | L | |
| TAT | AGG | GTT | GCG | CAT | AAA | CTG | TGG | AAT | GAA | GGG | AGG | AAA | CTA | TTA | GCT | 576 |
| L | L | L | Q | S | P | L | C | E | T | F | C | L | D | L | H | |
| CTT | GCA | TTG | CAA | AGC | CGA | ATA | AGC | GAG | GTT | TTT | GGC | ATT | GAC | ATA | CAT | 624 |
| P | A | A | A | L | D | G | L | L | D | D | L | G | L | C | | |
| CCA | GCG | GCA | AGA | ATT | GGG | GAG | GGA | ATA | TTG | TTG | GAT | CAT | GGA | ACT | GGA | 672 |
| N | V | L | C | E | L | D | T | L | G | N | G | V | S | L | L | |
| GTG | GTC | ATT | GGT | GAG | ACC | GCT | GTG | ATA | GGC | AAC | GGT | GTC | TCG | ATC | TTA | 720 |
| H | G | T | L | L | C | L | L | K | E | L | C | D | P | A | | |
| CAT | GGT | GTG | ACT | TTA | GGA | GGA | ACC | GGA | AAG | GAA | ACT | GGC | GAT | CGC | CAC | 768 |
| P | A | L | G | P | A | L | L | G | A | C | V | L | L | L | | |
| CCA | AAG | ATA | GGT | GAA | GGT | GCA | TTG | CTT | GGA | GCT | TGT | GTG | ACT | ATA | CTT | 816 |
| G | V | L | S | L | G | A | G | A | M | L | A | A | G | S | L | |
| GGT | AAC | ATA | AGC | ATA | GGT | GCT | GGA | GCA | ATG | GTA | GCT | GCA | GGT | TCA | CTT | 864 |
| V | L | K | D | V | P | S | A | S | V | L | A | G | N | P | A | |
| GTG | TTA | AAA | GAC | GTT | CCT | TCG | CAT | AGT | GTG | GTG | GCT | GGA | AAT | CCT | GCA | 912 |
| K | L | L | R | V | M | E | E | C | D | P | S | L | A | K | Y | |
| AAA | CTG | ATC | AGG | GTC | ATG | GAA | GAG | CAA | GAC | CCG | TCT | CTA | GCA | ATG | AAA | 960 |
| L | D | A | L | K | L | C | P | R | L | L | A | C | S | L | A | |
| CAC | GAT | GCT | ACT | AAA | GAG | TTC | TTT | CGA | CAT | GTA | GCT | GAT | GGT | TAC | AAA | 1008 |
| G | A | Q | S | N | B | D | S | L | D | A | G | D | P | L | A | |
| GGG | GCA | CAA | TCT | AAC | GGA | CCA | TCA | CTT | TCA | GCA | GGA | GAT | ACA | GAG | AAA | 1056 |
| L | L | L | L | S | D | L | L | L | L | L | L | L | L | L | L | |
| GGA | CAC | ACT | AAC | AGC | ACA | TCA | TGA | | | | | | | | | 1104 |

Figure 8: Sequence nucléotidique et peptidique du m RNA de la serine acetyltransferase SAT 2 putative chloroplastique d'*Arabidopsis thaliana* (L78444)

| Variable | Mean | SD | Min | Max | Median | Q1 | Q3 | Mode | Skewness | Kurtosis | Shapiro-Wilk | Normality |
|-----------------------|------|------|-----|------|--------|-----|------|------|----------|----------|--------------|-----------|
| Age | 35.2 | 12.5 | 18 | 65 | 32 | 25 | 40 | 30 | 0.15 | 2.5 | 0.98 | Normal |
| Gender | 1.2 | 0.4 | 1 | 2 | 1 | 1 | 2 | 1 | 0.05 | 0.5 | 0.95 | Normal |
| Education | 12.5 | 2.5 | 9 | 16 | 12 | 11 | 13 | 12 | 0.10 | 1.5 | 0.99 | Normal |
| Income | 1500 | 500 | 500 | 3000 | 1200 | 800 | 1800 | 1000 | 0.20 | 3.0 | 0.97 | Normal |
| Marital Status | 1.5 | 0.5 | 1 | 2 | 1 | 1 | 2 | 1 | 0.05 | 0.5 | 0.95 | Normal |
| Occupation | 2.5 | 1.5 | 1 | 5 | 2 | 1 | 3 | 2 | 0.10 | 1.5 | 0.99 | Normal |
| Health Status | 1.8 | 0.8 | 1 | 3 | 1 | 1 | 2 | 1 | 0.05 | 0.5 | 0.95 | Normal |
| Stress Level | 3.5 | 1.5 | 1 | 5 | 3 | 2 | 4 | 3 | 0.15 | 2.5 | 0.98 | Normal |
| Life Satisfaction | 4.2 | 1.2 | 1 | 5 | 4 | 3 | 5 | 4 | 0.10 | 1.5 | 0.99 | Normal |
| Work-Life Balance | 3.8 | 1.0 | 1 | 5 | 3 | 2 | 4 | 3 | 0.15 | 2.5 | 0.98 | Normal |
| Family Support | 4.5 | 1.0 | 1 | 5 | 4 | 3 | 5 | 4 | 0.10 | 1.5 | 0.99 | Normal |
| Community Involvement | 2.8 | 1.2 | 1 | 5 | 2 | 1 | 3 | 2 | 0.15 | 2.5 | 0.98 | Normal |
| Personal Growth | 3.2 | 1.0 | 1 | 5 | 3 | 2 | 4 | 3 | 0.15 | 2.5 | 0.98 | Normal |
| Overall Well-being | 4.0 | 1.0 | 1 | 5 | 4 | 3 | 5 | 4 | 0.10 | 1.5 | 0.99 | Normal |

| Variable | Mean | SD | Min | Max | Median | Q1 | Q3 | Mode | Skewness | Kurtosis | Shapiro-Wilk | Normality |
|------------------------|------|------|------|------|--------|------|------|------|----------|----------|--------------|-----------|
| Age | 35.2 | 12.5 | 18 | 65 | 32 | 25 | 40 | 30 | 0.15 | 2.5 | 0.98 | Normal |
| Gender | 1.2 | 0.4 | 1 | 2 | 1 | 1 | 2 | 1 | -0.1 | 0.5 | 0.95 | Normal |
| Marital Status | 2.1 | 0.8 | 1 | 3 | 2 | 1 | 3 | 2 | 0.2 | 1.2 | 0.92 | Normal |
| Education | 15.8 | 2.1 | 10 | 20 | 16 | 15 | 17 | 16 | -0.05 | 0.8 | 0.99 | Normal |
| Income | 4500 | 1500 | 2000 | 8000 | 4000 | 3500 | 5500 | 4000 | 0.1 | 1.5 | 0.96 | Normal |
| Occupation | 1.5 | 0.5 | 1 | 3 | 2 | 1 | 3 | 2 | -0.1 | 0.5 | 0.95 | Normal |
| Health Status | 2.5 | 0.5 | 1 | 3 | 2 | 2 | 3 | 2 | 0.1 | 0.8 | 0.97 | Normal |
| Stress Level | 3.2 | 1.0 | 1 | 5 | 3 | 2 | 4 | 3 | 0.2 | 1.2 | 0.93 | Normal |
| Life Satisfaction | 4.1 | 0.8 | 3 | 5 | 4 | 4 | 5 | 4 | -0.1 | 0.5 | 0.98 | Normal |
| Work-Life Balance | 3.8 | 0.9 | 2 | 5 | 4 | 3 | 5 | 4 | 0.1 | 0.8 | 0.96 | Normal |
| Family Support | 4.5 | 0.7 | 3 | 5 | 4 | 4 | 5 | 4 | -0.1 | 0.5 | 0.99 | Normal |
| Community Involvement | 2.8 | 0.6 | 1 | 4 | 3 | 2 | 4 | 3 | 0.1 | 0.8 | 0.97 | Normal |
| Personal Growth | 3.5 | 0.9 | 2 | 5 | 3 | 3 | 4 | 3 | 0.1 | 0.8 | 0.96 | Normal |
| Financial Stability | 3.0 | 0.8 | 2 | 4 | 3 | 2 | 4 | 3 | 0.1 | 0.8 | 0.97 | Normal |
| Emotional Well-being | 4.2 | 0.7 | 3 | 5 | 4 | 4 | 5 | 4 | -0.1 | 0.5 | 0.98 | Normal |
| Physical Health | 3.9 | 0.8 | 2 | 5 | 4 | 3 | 5 | 4 | 0.1 | 0.8 | 0.96 | Normal |
| Mental Health | 3.6 | 0.9 | 2 | 5 | 3 | 3 | 4 | 3 | 0.1 | 0.8 | 0.96 | Normal |
| Social Support | 4.0 | 0.7 | 3 | 5 | 4 | 4 | 5 | 4 | -0.1 | 0.5 | 0.98 | Normal |
| Work Satisfaction | 3.7 | 0.8 | 2 | 5 | 3 | 3 | 4 | 3 | 0.1 | 0.8 | 0.96 | Normal |
| Life Balance | 3.4 | 0.9 | 2 | 5 | 3 | 3 | 4 | 3 | 0.1 | 0.8 | 0.96 | Normal |
| Family Harmony | 4.3 | 0.6 | 3 | 5 | 4 | 4 | 5 | 4 | -0.1 | 0.5 | 0.99 | Normal |
| Personal Fulfillment | 3.8 | 0.9 | 2 | 5 | 3 | 3 | 4 | 3 | 0.1 | 0.8 | 0.96 | Normal |
| Financial Security | 3.1 | 0.8 | 2 | 4 | 3 | 2 | 4 | 3 | 0.1 | 0.8 | 0.97 | Normal |
| Emotional Stability | 4.1 | 0.7 | 3 | 5 | 4 | 4 | 5 | 4 | -0.1 | 0.5 | 0.98 | Normal |
| Physical Fitness | 3.9 | 0.8 | 2 | 5 | 4 | 3 | 5 | 4 | 0.1 | 0.8 | 0.96 | Normal |
| Mental Resilience | 3.6 | 0.9 | 2 | 5 | 3 | 3 | 4 | 3 | 0.1 | 0.8 | 0.96 | Normal |
| Social Connection | 4.0 | 0.7 | 3 | 5 | 4 | 4 | 5 | 4 | -0.1 | 0.5 | 0.98 | Normal |
| Work Engagement | 3.7 | 0.8 | 2 | 5 | 3 | 3 | 4 | 3 | 0.1 | 0.8 | 0.96 | Normal |
| Life Purpose | 3.4 | 0.9 | 2 | 5 | 3 | 3 | 4 | 3 | 0.1 | 0.8 | 0.96 | Normal |
| Family Unity | 4.3 | 0.6 | 3 | 5 | 4 | 4 | 5 | 4 | -0.1 | 0.5 | 0.99 | Normal |
| Personal Achievement | 3.8 | 0.9 | 2 | 5 | 3 | 3 | 4 | 3 | 0.1 | 0.8 | 0.96 | Normal |
| Financial Independence | 3.0 | 0.8 | 2 | 4 | 3 | 2 | 4 | 3 | 0.1 | 0.8 | 0.97 | Normal |
| Emotional Balance | 4.1 | 0.7 | 3 | 5 | 4 | 4 | 5 | 4 | -0.1 | 0.5 | 0.98 | Normal |
| Physical Health Index | 3.9 | 0.8 | 2 | 5 | 4 | 3 | 5 | 4 | 0.1 | 0.8 | 0.96 | Normal |
| Mental Health Index | 3.6 | 0.9 | 2 | 5 | 3 | 3 | 4 | 3 | 0.1 | 0.8 | 0.96 | Normal |
| Social Support Index | 4.0 | 0.7 | 3 | 5 | 4 | 4 | 5 | 4 | -0 | | | |

| Variable | Mean | SD | Min | Max | Median | Q1 | Q3 | Mode | Skewness | Kurtosis | Shapiro-Wilk | Normality |
|-----------------------|------|------|-----|------|--------|-----|------|------|----------|----------|--------------|-----------|
| Age | 35.2 | 12.5 | 18 | 65 | 32 | 25 | 40 | 30 | 0.15 | 2.10 | 0.98 | Normal |
| Gender | 1.2 | 0.4 | 1 | 2 | 1 | 1 | 2 | 1 | -0.10 | 0.05 | 0.99 | Normal |
| Education | 12.5 | 2.1 | 9 | 16 | 12 | 11 | 13 | 12 | 0.05 | 0.10 | 0.99 | Normal |
| Income | 1500 | 500 | 500 | 3000 | 1200 | 800 | 1800 | 1000 | 0.20 | 1.50 | 0.95 | Normal |
| Marital Status | 1.5 | 0.5 | 1 | 2 | 1 | 1 | 2 | 1 | -0.05 | 0.02 | 0.99 | Normal |
| Occupation | 2.5 | 1.2 | 1 | 5 | 2 | 1 | 3 | 2 | 0.10 | 0.50 | 0.97 | Normal |
| Health Status | 1.8 | 0.6 | 1 | 3 | 1 | 1 | 2 | 1 | -0.15 | 0.08 | 0.99 | Normal |
| Stress Level | 3.2 | 1.5 | 1 | 5 | 3 | 2 | 4 | 3 | 0.10 | 0.80 | 0.96 | Normal |
| Life Satisfaction | 4.5 | 1.0 | 3 | 6 | 4 | 4 | 5 | 4 | -0.05 | 0.15 | 0.99 | Normal |
| Work-Life Balance | 3.8 | 1.2 | 2 | 5 | 3 | 3 | 4 | 3 | 0.05 | 0.60 | 0.97 | Normal |
| Family Support | 4.2 | 0.8 | 3 | 5 | 4 | 4 | 5 | 4 | -0.02 | 0.10 | 0.99 | Normal |
| Community Involvement | 2.8 | 1.1 | 1 | 5 | 2 | 2 | 3 | 2 | 0.15 | 0.70 | 0.96 | Normal |
| Personal Growth | 3.5 | 1.3 | 2 | 5 | 3 | 3 | 4 | 3 | 0.08 | 0.90 | 0.97 | Normal |
| Overall Well-being | 4.0 | 1.1 | 3 | 5 | 4 | 4 | 5 | 4 | -0.03 | 0.12 | 0.99 | Normal |

8/12




Figure 10 Dendrogramme des serine acétyltransferase issues de plusieurs organismes.




Figure 11: Procédure de clonage de l'OTP/Serine acétyltransférase SAT3 ou SAT (insensible à la cystéine, par exemple SAT1 tronqué) dans le vecteur pBI121.




Figure 12: Procédure de clonage de la Serine acétyltransférase SAT1' ; SAT1 ; SAT2 ; SAT3, SAT3' ; SAT4, ou toutes SATs dans le vecteur pBI121.

9/12




Figure 13




Figure 14




Figure 15

10/12




Figure 16




Figure 17




Figure 18

11/12




Figure 19




Figure 20




Figure 21

| | 1990 | 1991 | 1992 | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | 2050 | 2051 | 2052 | 2053 | 2054 | 2055 | 2056 | 2057 | 2058 | 2059 | 2060 | 2061 | 2062 | 2063 | 2064 | 2065 | 2066 | 2067 | 2068 | 2069 | 2070 | 2071 | 2072 | 2073 | 2074 | 2075 | 2076 | 2077 | 2078 | 2079 | 2080 | 2081 | 2082 | 2083 | 2084 | 2085 | 2086 | 2087 | 2088 | 2089 | 2090 | 2091 | 2092 | 2093 | 2094 | 2095 | 2096 | 2097 | 2098 | 2099 | 2100 |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| 1990 | 1991 | 1992 | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | 2050 | 2051 | 2052 | 2053 | 2054 | 2055 | 2056 | 2057 | 2058 | 2059 | 2060 | 2061 | 2062 | 2063 | 2064 | 2065 | 2066 | 2067 | 2068 | 2069 | 2070 | 2071 | 2072 | 2073 | 2074 | 2075 | 2076 | 2077 | 2078 | 2079 | 2080 | 2081 | 2082 | 2083 | 2084 | 2085 | 2086 | 2087 | 2088 | 2089 | 2090 | 2091 | 2092 | 2093 | 2094 | 2095 | 2096 | 2097 | 2098 | 2099 | 2100 | |

SEQUENCE LISTING

<140>
<141>

```
<160> 27
<170> PatentIn Ver. 2.1
```

<220>
<221> CDS

[illegible][illegible]

cat caa tct cca tca aag gag aaa cta tct tcc gtt acc caa tcc gat 102
His Gln Ser Pro Ser Lys Glu Lys Leu Ser Ser Val Thr Gln Ser Asp
10 15 20

| | | | | | | | | | | | | | | | | |
|-------------------|------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------------------|-------------------|-----|
| gaa Glu 25 | gca Ala | gaa Glu | gca Ala | gag Ala | tca Ser 30 | gca Ala | gag Ala | ata Ile | tct Ser | gcg Ala 35 | gca Ala | gct Ala | gca Ala | gat Asp | gag Ala 40 | 150 |
| gaa Glu | gct Ala | gcc Ala | gga Gly | tta Leu 45 | tgg Trp | aca Thr | cag Gln | att Ile | aag Lys 50 | gag Ala | gaa Glu | gct Ala | cgc Arg | cgt Arg 55 | gat Asp | 198 |
| gct Ala | gag Glu | gcg Ala | gag Glu 60 | cca Pro | gct Ala | tta Leu | gct Ala | agc Ser 65 | tat Tyr | cta Leu | tat Tyr | tgg Ser | acg Thr 70 | att Ile | cct Leu | 246 |
| tct Ser | cct His | tgg Ser 75 | tct Ser | ctt Leu | gaa Glu | cga Arg | tct Ser 80 | att Ile | tgg Ser | tct Phe | cct His | cta Leu 85 | gga Gly | aac Asn | aag Lys | 294 |
| ctt Leu | tgt Cys 90 | tcc Ser | tca Ser | acg Thr | ctt Leu | tta Leu 95 | tcc Ser | aca Thr | ctt Leu | tta Leu | tac Tyr 100 | gat Asp | ctg Leu | ttc Phe | tta Leu | 342 |
| aac Asn 105 | act Thr | ttt Phe | tcc Ser | tcc Ser | gat Asp 110 | cct Pro | tct Ser | ctt Leu | cgt Arg | aac Asn 115 | gcc Ala | acc Thr | gtc Val | gca Ala | gat Asp 120 | 390 |
| cta Leu | cgc Arg | gct Ala | gct Ala | cgt Arg 125 | ggt Val | cgt Arg | gat Asp | cct Pro | gct Ala 130 | tgt Cys | atc Ile | tgg Ser | ttc Phe 135 | tct Ser | cct His | 438 |
| tgt Cys | ctc Leu | ctc Leu | aat Asn 140 | tac Tyr | aan Lys | ggc Gly | ttc Phe 145 | tta Leu | gct Ala | att Ile | cag Gln | gag Ala | tat His 150 | cgt Arg | gta Val | 486 |
| tca Ser | cac His | aag Lys 155 | cta Leu | tgg Trp | aca Thr | caa Gln | tca Ser 160 | cgg Arg | aag Lys | cca Pro | tta Leu | gca Ala 165 | tta Leu | gct Ala | cta Leu | 534 |
| cac His 170 | tca Ser | aga Arg | atc Ile | tcc Ser | gat Asp | gta Val 175 | ttc Phe | gct Ala | ggt Val | gat Asp 180 | atc Ile | cct His | cca Pro | gca Ala | gcg Ala | 582 |
| aag Lys 185 | atc Ile | gga Gly | aaa Lys | ggg Gly | ata Ile 190 | ctt Leu | cta Leu | gac Asp | cac His | gca Ala 195 | acc Thr | gga Gly | gtt Val | gtc Val | gtc Val 200 | 630 |
| gga Gly | gaa Glu | aca Thr | gcg Ala 205 | gtg Val | att Ile | ggg Gly | aac Asn | aat Asn | gtt Val 210 | tca Ser | atc Ile | ctt Leu | cac His 215 | cct His | gtg Val | 678 |
| aca Thr | cta Leu | ggt Gly | gga Gly 220 | aca Thr | ggt Gly | aaa Lys | gct Ala | tgt Cys 225 | gga Gly | gat Asp | aga Arg | cct His | ccg Pro 230 | aag Lys | atc Ile | 726 |
| ggt Gly | gac Asp | ggt Gly 235 | tgt Cys | ttg Leu | att Ile | gga Gly | gct Ala 240 | gga Gly | gcg Ala | act Thr | att Ile | ctt Leu 245 | gga Gly | aat Asn | gtg Val | 774 |
| aag Lys 250 | att Ile | ggt Gly | gca Ala | ggt Gly | gct Ala 255 | aaa Lys | gta Val | gga Gly | gct Ala | ggt Gly 260 | tct Ser | gtt Val | gtg Val | ctg Leu | att Ile | 822 |
| gac Asp 265 | gtg Val | cct Pro | tgt Cys | cga Arg | ggt Gly 270 | act Thr | gcg Ala | gtt Val | ggg Gly | aat Asn 275 | ccg Pro | gcg Ala | aga Arg | ctt Leu | gtc Val 280 | 870 |

gat cct gct tgt ata agc tac gtt cat tgt ttc ctt cac ttt aaa ggc 534
Asp Pro Ala Cys Ile Ser Tyr Val His Cys Phe Leu His Phe Lys Gly
155 160 165

Gac ttc aca atg tcc cta tat atg ctc cgt tca tct tct tca cac atc 102
 His Phe Thr Met Ser Leu Tyr Met Leu Arg Ser Ser Ser Pro His Ile
 10 15 20

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| aat | cat | cac | tct | tct | ctt | ctt | ctt | tct | tct | gtt | tcc | tcc | aaa | tcc | aaa | 150 |
| Asn | His | His | Ser | Phe | Leu | Leu | Pro | Ser | Phe | Val | Ser | Ser | Lys | Phe | Lys | 25 |
| | | | | | 30 | | | | | 35 | | | | | 40 | |
| cac | cat | act | tta | tct | cct | cct | cct | tct | cct | cct | cct | cct | cct | cct | atg | 198 |
| His | His | Thr | Leu | Ser | Pro | Pro | Pro | Ser | Pro | Pro | Pro | Pro | Pro | Pro | Met | 45 |
| | | | | 45 | | | | | 50 | | | | | 55 | | |
| gct | gcg | tgc | atc | gac | acc | tgc | cgc | act | ggc | aaa | ccc | cag | att | tct | cct | 246 |
| Ala | Ala | Cys | Ile | Asp | Thr | Cys | Arg | Thr | Gly | Lys | Pro | Gln | Ile | Ser | Pro | 60 |
| | | | 60 | | | | | 65 | | | | | 70 | | | |
| cgc | gat | tct | tct | aaa | cac | cac | gac | gat | gaa | tct | ggc | tct | cgt | tac | atg | 294 |
| Arg | Asp | Ser | Ser | Lys | His | His | Asp | Asp | Glu | Ser | Gly | Phe | Arg | Tyr | Met | 75 |
| | | | | | | | 80 | | | | | 85 | | | | |
| aac | tac | ttc | cgt | tat | cct | gat | cga | tct | tcc | ttc | aat | gga | acc | cag | acc | 342 |
| Asn | Tyr | Phe | Arg | Tyr | Pro | Asp | Arg | Ser | Ser | Phe | Asn | Gly | Thr | Gln | Thr | 90 |
| | | | | | 95 | | | | | | 100 | | | | | |
| aaa | acc | ctc | cat | act | cgt | cct | ttg | ctt | gaa | gat | ctc | gat | cgc | gac | gct | 390 |
| Lys | Thr | Leu | His | Thr | Arg | Pro | Leu | Leu | Glu | Asp | Leu | Asp | Arg | Asp | Ala | 105 |
| | | | | | 110 | | | | 115 | | | | | | 120 | |
| gaa | gtc | gat | gat | gtt | tgg | gcc | aaa | atc | cga | gaa | gag | gct | aaa | tct | gat | 438 |
| Glu | Val | Asp | Asp | Val | Trp | Ala | Lys | Ile | Arg | Glu | Glu | Ala | Lys | Ser | Asp | 125 |
| | | | | 125 | | | | | 130 | | | | | 135 | | |
| atc | goc | aaa | gaa | cct | att | gtt | tcc | gct | tat | tat | cac | gct | tcc | att | gtt | 486 |
| Ile | Ala | Lys | Glu | Pro | Ile | Val | Ser | Ala | Tyr | Tyr | His | Ala | Ser | Ile | Val | 140 |
| | | | | 140 | | | | 145 | | | | | 150 | | | |
| tct | cag | cgt | tcc | ttg | gaa | gct | gcg | ttg | gcg | aat | act | tta | tct | gtt | aaa | 534 |
| Ser | Gln | Arg | Ser | Leu | Glu | Ala | Ala | Leu | Ala | Asn | Thr | Leu | Ser | Val | Lys | 155 |
| | | | | 155 | | | 160 | | | | | 165 | | | | |
| ctc | agc | aat | ttg | aat | ctt | cca | agc | aac | acg | ctt | tcc | gat | ttg | tcc | tct | 582 |
| Leu | Ser | Asn | Leu | Asn | Leu | Pro | Ser | Asn | Thr | Leu | Phe | Asp | Leu | Phe | Ser | 170 |
| | | | | | | 175 | | | | | 180 | | | | | |
| ggt | gtt | ctt | caa | gga | aac | cca | gat | att | gtt | gaa | tct | gtc | aag | cta | gat | 630 |
| Gly | Val | Leu | Gln | Gly | Asn | Pro | Asp | Ile | Val | Glu | Ser | Val | Lys | Leu | Asp | 185 |
| | | | | 190 | | | | | 195 | | | | | 200 | | |
| ctt | tta | gct | gtt | aag | gag | aga | gat | cct | gct | tgt | ata | agc | tac | gtt | cat | 678 |
| Leu | Leu | Ala | Val | Lys | Glu | Arg | Asp | Pro | Ala | Cys | Ile | Ser | Tyr | Val | His | 205 |
| | | | | 205 | | | | 210 | | | | | | 215 | | |
| tgt | tcc | ctt | cac | ttt | aaa | ggc | ttc | ctc | gct | tgt | caa | gcg | cat | cgt | att | 726 |
| Cys | Phe | Leu | His | Phe | Lys | Gly | Phe | Leu | Ala | Cys | Gln | Ala | His | Arg | Ile | 220 |
| | | | | 220 | | | 225 | | | | | 230 | | | | |
| g | | | | | | | | | | | | | | | | |

| | |
|---|------|
| ggt gag acg cgc gct gtg ggg aac aat gtt tgg att ctc cat aac gtt | 913 |
| Gly Glu Thr Ala Val Val Gly Asn Asn Val Ser Ile Leu His Asn Val | |
| 285 290 295 | |
| acg ctt gga gga acg ggg aaa cag tgt gga gat agg cac ccg aag att | 966 |
| Thr Leu Gly Gly Thr Gly Lys Gln Cys Gly Asp Arg His Pro Lys Ile | |
| 300 305 310 | |
| ggc gat ggg gtt ttg att gga gct ggg act tgt att ttg ggg aat atc | 1014 |
| Gly Asp Gly Val Leu Ile Gly Ala Gly Thr Cys Ile Leu Gly Asn Ile | |
| 315 320 325 | |
| acg att ggt gaa gga gct aag att ggt gcg ggg tgg gtg gtg ttg aaa | 1062 |
| Thr Ile Gly Glu Gly Ala Lys Ile Gly Ala Gly Ser Val Val Leu Lys | |
| 330 335 340 | |
| gac gtg ccg ccg cgt acg acg gct gtt gga aat ccg gcg aag ttg ctt | 1110 |
| Asp Val Pro Pro Arg Thr Thr Ala Val Gly Asn Pro Ala Arg Leu Leu | |
| 345 350 355 360 | |
| ggt ggt aaa gat aat ccg aaa acg cat gac aag att cct ggt ttg act | 1158 |
| Gly Gly Lys Asp Asn Pro Lys Thr His Asp Lys Ile Pro Gly Leu Thr | |
| 365 370 375 | |
| atg gac cag acg tgg cat ata tcc gag tgg tgg gat tat gta att | 1203 |
| Met Asp Gln Thr Ser His Ile Ser Glu Trp Ser Asp Tyr Val Ile | |
| 380 385 390 | |
| tgaaaaagtc | 1213 |
| | |
| <210> 5 | |
| <211> 1080 | |
| <212> DNA | |
| <213> Arabidopsis thaliana | |
| | |
| <220> | |
| <221> CDS | |
| <222> (1)..(1080) | |
| | |
| <220> | |
| <221> transit peptide | |
| <222> (1)..(96) | |
| | |
| <400> 5 | |
| atg gtg gat cta cct tcc ttt agc ctc ctt ttt gct ttt tcc gtc tct | 48 |
| Met Val Asp Leu Ser Ser Phe Ser Leu Leu Phe Ala Phe Ser Val Ser | |
| 1 5 10 15 | |
| ctc tot ttt gtc caa tca aaa aga gtt tgt gat tct tct tta tgg tct | 96 |
| Leu Ser Phe Val Gln Ser Lys Arg Val Cys Asp Ser Ser Leu Ser Ser | |
| 20 25 30 | |
| cct tgg aga gat atg aat ggc gat gag ctt cct ttc gag agt ggt ttc | 144 |
| Pro Trp Arg Asp Met Asn Gly Asp Glu Leu Pro Phe Glu Ser Gly Phe | |
| 35 40 45 | |
| gag gtc tac gct aag gga act cat aag tca gag ttt gac tgg aat ttg | 192 |
| Glu Val Tyr Ala Lys Gly Thr His Lys Ser Glu Phe Asp Ser Asn Leu | |
| 50 55 60 | |
| ctt gat cct cgt tct gat cct att tgg gat gct ata aga gaa gaa gct | 240 |
| Leu Asp Pro Arg Ser Asp Pro Ile Trp Asp Ala Ile Arg Glu Glu Ala | |
| 65 70 75 80 | |

| | |
|---|------|
| aaa ctt gag gca gag aaa gag cct att ctg agt agc ttc ttg tat gct | 288 |
| Lys Leu Glu Ala Glu Lys Glu Pro Ile Leu Ser Ser Phe Leu Tyr Ala | |
| 85 90 95 | |
| ggc atc tta gca cat gat tgt tta gag caa gct tta ggg ttt gtt cta | 336 |
| Gly Ile Leu Ala His Asp Cys Leu Glu Gln Ala Leu Gly Phe Val Leu | |
| 100 105 110 | |
| gcc aac cgt ctc caa aac cca acc ttg ttg gca acc caa ctc ttg gat | 384 |
| Ala Asn Arg Leu Gln Asn Pro Thr Leu Leu Ala Thr Gln Leu Leu Asp | |
| 115 120 125 | |
| ata ttt tat ggt gtt atg atg cat gac aaa ggt att dag agt tcg att | 432 |
| Ile Phe Tyr Gly Val Met Met His Asp Lys Gly Ile Gln Ser Ser Ile | |
| 130 135 140 | |
| cgc gat gat ctc cag gca ttt aaa gat cgt gat cct gct tgt ctg tcg | 480 |
| Arg His Asp Leu Gln Ala Phe Lys Asp Arg Asp Pro Ala Cys Leu Ser | |
| 145 150 155 160 | |
| tat agt tct gct att tta cat ctg aag ggt tat cat gcg tta caa gca | 528 |
| Tyr Ser Ser Ala Ile Leu His Leu Lys Gly Tyr His Ala Leu Gln Ala | |
| 165 170 175 | |
| tat agg gtt gcg cat aaa ctg tgg aat gaa ggg agg aaa cta tta gct | 576 |
| Tyr Arg Val Ala His Lys Leu Trp Asn Glu Gly Arg Lys Leu Leu Ala | |
| 180 185 190 | |
| ctc gca ttg caa agc cga ata agc gag gtt ttc ggc att gac ata cat | 624 |
| Leu Ala Leu Gln Ser Arg Ile Ser Glu Val Phe Gly Ile Asp Ile His | |
| 195 200 205 | |
| cca gcg gca aga att ggg gag gga ata ctg ttg gat cat gga act gga | 672 |
| Pro Ala Ala Arg Ile Gly Glu Gly Ile Leu Leu Asp His Gly Thr Gly | |
| 210 215 220 | |
| gtg gtc att ggt gag acc gct gcg ata ggc aac ggt gtc tcg atc tta | 720 |
| Val Val Ile Gly Glu Thr Ala Val Ile Gly Asn Gly Val Ser Ile Leu | |
| 225 230 235 240 | |
| cat ggt gtg act tta gga gga acc gga aag gaa act ggc gat cgc cac | 768 |
| His Gly Val Thr Leu Gly Gly Thr Gly Lys Glu Thr Gly Asp Arg His | |
| 245 250 255 | |
| cca aag ata ggt gaa ggt gca ttg ctt gga gct tgt gtg act ata ctt | 816 |
| Pro Lys Ile Gly Glu Gly Ala Leu Leu Gly Ala Cys Val Thr Ile Leu | |
| 260 265 270 | |
| ggt aac ata agc ata ggt gct gga gca atg gta gct gca ggt tca ctt | 864 |
| Gly Asn Ile Ser Ile Gly Ala Gly Ala Met Val Ala Ala Gly Ser Leu | |
| 275 280 285 | |
| gtg tta aaa gac gtc cct tcg cat agt gtg gtg gct gga aat cct gca | 912 |
| Val Leu Lys Asp Val Pro Ser His Ser Val Val Ala Gly Asn Pro Ala | |
| 290 295 300 | |
| aaa ctg atc agg gtc atg gaa gag caa gac ccg tct cta gca atg aaa | 960 |
| Lys Leu Ile Arg Val Met Glu Glu Gln Asp Pro Ser Leu Ala Met Lys | |
| 305 310 315 320 | |
| cac gat gct act aaa gag ttc ttt cga cat gca gct gat ggt tac aaa | 1008 |
| His Asp Ala Thr Lys Glu Phe Phe Arg His Val Ala Asp Gly Tyr Lys | |
| 325 330 335 | |

tog tat agt tog gct att tta cat ctg aag ggc tat ctt gca ctg cag 528
 Ser Tyr Ser Ser Ala Ile Leu His Leu Lys Gly Tyr Leu Ala Leu Gln
 165 170 175

<220>

<223> Artificial sequence description:
synthetic oligonucleofide

49

<213> Artificial sequence

<223> Artificial sequence description:
synthetic oligonucleotide

43

<213> Artificial sequence

<223> Artificial sequence description:
synthetic oligonucleotide

67

<213> Artificial sequence

<223> Artificial sequence description:
synthetic oligonucleotide

40



COMBINED DECLARATION AND POWER OF ATTORNEY

Atty. Docket No.:
PH-98/080

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHOD FOR INCREASING THE CONTENT OF SULPHUR COMPOUNDS AND IN PARTICULAR OF CYSTEINE, METHIONINE AND GLUTATHIONE IN PLANTS AND PLANTS OBTAINED

the specification of which was filed on February 22, 2000 as Serial No. 09/486,334 and PCT International application no. PCT/FR99/03179 filed December 17, 1999

and including all the amendments through the date hereof.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s) for which Priority is Claimed

| | | |
|-----------------|---------|----------|
| FR 98/16163 | France | 12/17/98 |
| Application No. | Country | Date |

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application

| | | |
|-----------------|------|--------|
| Application No. | Date | Status |
|-----------------|------|--------|


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both; under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

16
Rudolf E. Hutz, Reg. No. 22,397; Harold Pezzner, Reg. No. 22,112; Richard M. Beck, Reg. No. 22,580; Paul E. Crawford, Reg. No. 24,397; Patricia Smink Rogowski, Reg. No. 33,791; Robert G. McMorrow, Jr., Reg. No. 30,962; Ashley I. Pezzner, Reg. No. 35,646; William E. McShane, Reg. No. 32,707; Mary W. Bourke, Reg. No. 30,982; Gerard M. O'Rourke, Reg. No. 39,794; James M. Olsen, Reg. No. 40,408; Francis DiGiovanni, Reg. No. 37,310; Christine M. Hansen, Reg. No. 40,634; Frank Z. Yang, Reg. No. 35,417; Eric J. Evain, Reg. No. 42,517; and Daniel C. Mulveny, Reg. No. 45,897; all of P.O. Box 2207, Wilmington, Delaware 19899-2007 my attorneys with full power of substitution and revocation.

| | | | |
|--|--|--|-----------------------|
| Send Correspondence To: Connolly, Bove, Lodge & Hutz, LLP P.O. Box 2207 Wilmington, Delaware 19899-2207 | | Direct Telephone Calls To: (302) 658-9141 | |
| FULL NAME OF SOLE OR FIRST INVENTOR DROUX Michel | | INVENTOR'S SIGNATURE <i>[Signature]</i> | DATE May 24, 2000 |
| RESIDENCE 32 Avenue de Lauterbourg 69160 Tassin le Sec POST OFFICE ADDRESS FRX | | CITIZENSHIP FRENCH | |
| FULL NAME OF SECOND JOINT INVENTOR DEROSE Richard | | INVENTOR'S SIGNATURE <i>[Signature]</i> | DATE June 15, 2000 |
| RESIDENCE 31, rue du Bois Guillaume 91000 Evry POST OFFICE ADDRESS FRX | | CITIZENSHIP USA | |
| FULL NAME OF THIRD JOINT INVENTOR JOB Dominique | | INVENTOR'S SIGNATURE <i>[Signature]</i> | DATE May 24, 2000 |
| RESIDENCE 131, rue Duguesclin 69003 Lyon POST OFFICE ADDRESS FRX | | CITIZENSHIP FRENCH | |
| FULL NAME OF FOURTH JOINT INVENTOR LAPPARTIENT Anne | | INVENTOR'S SIGNATURE <i>[Signature]</i> | DATE May 24, 2000 |
| RESIDENCE 13A, rue Philippe Gonnard 69005 Lyon POST OFFICE ADDRESS FRX | | CITIZENSHIP French | |

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ Scanned copy is best available.

Sequences listing

Specification, Drawing,